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Abstract
Despite the improved outcome associated with current treatment strategies ofpediatric acute
lymphoblastic leukemia (ALL), relapse still represents a major challenge. Pediatric ALL demonstrates
branched evolution in response to selective pressure exerted by therapy; relapse founder clones emerge
from pre-leukemic clones or minor subclones present at diagnosis. It is hence crucial to develop
biomarkers capable of tracking subclones throughout therapy. Current practices for monitoring disease
response in leukemia rely on the analysis of BM biopsy sample at specific time points throughout therapy.
Not only the invasiveness of the BM biopsy hinders the sequential sampling, but also, the currently
implied techniques are associated with a lack of sensitivity to detect subclones other than the major
diagnostic clone. Somatic mutation detection in circulating-tumor DNA (Ct-DNA) offers a new venue for
non-invasive studying of genetic heterogeneity and tracking clonal dynamics throughout therapy. Here, we
employ targeted Next-Generation Sequencing (NGS) using a specifically designed ALL custom gene panel
for Ct-DNA analysis of sequential plasma samples of 14 pediatric ALL during remission induction therapy.
Utilizing 1 ml of plasma, Ct-DNA successfully captured all the clinically relevant somatic single nucleotide
variants (SNVs) detected by whole exome sequencing (WES) in bone marrow (BM) biopsy samples at
diagnosis. Moreover, we were able to show the ability of Ct-DNA analysis to track the change in the
mutant allele fraction (MAF) across multiple time points as well as, to detect mutations in Flowcytometry
(FC) MRD-negative patients. Taken together, sequential analysis of Ct-DNA in plasma demonstrates a role,
as a non-invasive technique, for detecting the clonal composition as well as, tracking clonal dynamics in
pediatric ALL.
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ABSTRACT
Despite the improved outcome associated with current treatment strategies of
pediatric acute lymphoblastic leukemia (ALL), relapse still represents a major challenge.
Pediatric ALL demonstrates branched evolution in response to selective pressure exerted
by therapy; relapse founder clones emerge from pre-leukemic clones or minor subclones
present at diagnosis. It is hence crucial to develop biomarkers capable of tracking
subclones throughout therapy. Current practices for monitoring disease response in
leukemia rely on the analysis of BM biopsy sample at specific time points throughout
therapy. Not only the invasiveness of the BM biopsy hinders the sequential sampling, but
also, the currently implied techniques are associated with a lack of sensitivity to detect
subclones other than the major diagnostic clone. Somatic mutation detection in
circulating-tumor DNA (Ct-DNA) offers a new venue for non-invasive studying of
genetic heterogeneity and tracking clonal dynamics throughout therapy. Here, we employ
targeted Next-Generation Sequencing (NGS) using a specifically designed ALL custom
gene panel for Ct-DNA analysis of sequential plasma samples of 14 pediatric ALL during
remission induction therapy. Utilizing 1 ml of plasma, Ct-DNA successfully captured all
the clinically relevant somatic single nucleotide variants (SNVs) detected by whole
exome sequencing (WES) in bone marrow (BM) biopsy samples at diagnosis. Moreover,
we were able to show the ability of Ct-DNA analysis to track the change in the mutant
allele fraction (MAF) across multiple time points as well as, to detect mutations in
Flowcytometry (FC) MRD-negative patients. Taken together, sequential analysis of CtDNA in plasma demonstrates a role, as a non-invasive technique, for detecting the clonal
composition as well as, tracking clonal dynamics in pediatric ALL.
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CHAPTER 1. INTRODUCTION
Overview
Acute Lymphoblastic Leukemia (ALL) shows the highest prevalence among
children and adolescents in the United States, comprising one fifth of the cancers in
persons aged below 20 years. [1] ALL is either B-cell or T-cell, both of which constitute
different subtypes, harboring chromosomal alterations as well as, secondary sequence
mutations. [2] ALL is polyclonal at diagnosis; most of B-cell of leukemias having
multiple subclonal mutations at diagnosis.[3] Chromosomal alterations, which
compromise an early initiating event, have been used to risk stratify children with ALL,
together with treatment response (i.e. minimal residual disease (MRD) at specified time
points)[4, 5] Still, within the favorable risk group, a substantial number of patients,
relapse [5]. A number of studies have addressed the change in the clonal dynamics and
mutational landscape at relapse using matched used matched diagnosis/remission/relapse
samples [3, 6, 7] Mutant allele frequency/fraction (MAF) defined as "the number of
mutant reads divided by the total number of reads – coverage – at a specific genomic
position" [8] changes from diagnosis to relapse, where in most cases, one minor clone
that survived therapy and acquired additional mutations becomes the relapse founder
clone [3]. Mutations in different pathways have shown to be enriched at relapse, of which
NT5C2 and CREBBP have been shown to confer resistance to 6-mercaptopurine (6-MP)
& glucocorticoids, respectively.[6, 9].
It has been postulated that therapy contributes to clonal evolution through either
differential sensitivity or through mass extinction [10]. Besides, an increase in subclonal
MAF preceded clinical relapse In one study, ultra-deep sequencing of sequential samples
(4 patients) during maintenance phase, showed an exponential increase in the percentage
of PRSP1 mutation (conferring resistance to 6MP) preceded clinical relapse, hence,
indicating that PRSP1 could drive relapse. [11] Additionally, spatial heterogeneity
at relapse has been demonstrated; a recent study had shown that in a case with combined
(BM and testicular relapse), the testicular relapse represented an independent subclone
from the BM relapse. [12]
Despite the advancement in treatment protocols, the currently applied strategies
for ALL diagnosis and follow up have two main limitations hindering the detection of
clonal diversity as diagnosis and longitudinal follow up of clonal evolution. First, single
site BM biopsy at diagnosis lack the ability to capture tumor heterogeneity associated
with spatially separated subclones.[13, 14]. Second, flow cytometry (FC) as well as,
Polymerase Chain Reaction (PCR)-based methods for disease monitoring fail to detect
evolved leukemic clones that were not initially detected at diagnosis [15, 16]. Thus,
prohibiting early detection of somatic mutations that confer therapy resistance and
consequently, relapse.
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In the light of the above findings, the incorporation of a sensitive biomarker
capable of capturing temporal and spatial heterogeneity, would have a potential
implication in real-time monitoring of the disease and guiding therapy accordingly.
Tumor derived Cell-free DNA or Circulating tumor DNA (Ct-DNA) has been
isolated and characterized from the plasma of cancer patients, together with non-tumor
derived Cell-free DNA (Cf-DNA). Ct-DNA is 167 bp double stranded DNA fragments
released from apoptotic/necrotic tumor cells (12,13). Derived from different
malignant subclones, Ct-DNA offers a representation of tumor heterogeneity,
consequently, providing a better characterization of disease behavior than does currently
used quantitative methods based on the detection of the most dominant diagnostic clone.
Several proof-of-concept studies have demonstrated the utility of Ct-DNA in molecular
profiling, monitoring of disease response, tracking therapy resistance, as well as,
unraveling the heterogeneity of resistance mechanisms. [14, 17, 18]
Capturing heterogeneity at diagnosis, and more importantly, early detection of
evolving resistant subclones have a number of therapeutic implications, i.e., the
incorporation of newly discovered targeted therapies and small molecules to reverse a
phenotype or to use different therapies sequentially to evade evolving clones. (3,10,11).
In this project, we evaluated the utility of detecting somatic mutations in plasma
Ct-DNA as a non-invasive technique for molecular profiling at diagnosis, as well as
monitoring tumor dynamics throughout therapy. We performed Next-generation
sequencing (NGS) of Ct-DNA (whole exome sequencing (WES) or targeted sequencing)
from sequential plasma samples withdrawn during remission induction therapy. We then
compared the MAF across different time points as well as, between BM biopsy, and
plasma samples at diagnosis.
Our preliminary data showed that Whole Exome Sequencing (WES) is capable of
detecting the change in predominance of subclonal somatic mutations in Ct-DNA. We
employed WES for the first recruited patients; however, data analysis was challenged by
the large number of mutations detected, rendering it difficult to discriminate true
mutations from false positive ones. Hence, for the next group of patients, we applied
targeted sequencing using a specifically designed ALL customized gene panel. Our longterm goal is to incorporate Ct-DNA in the clinical protocols as a minimally invasive
biomarker for comprehensive molecular profiling, and longitudinal monitoring of disease
response in pediatric ALL.
Aim of the Work
NGS was applied to study somatic mutations in Ct-DNA in peripheral blood
(PB)/bone marrow (BM) plasma. Plasma samples were obtained at diagnosis, at specified
time points during, and at the end of remission induction therapy. MAF was calculated
for all the specified time points. Study specific aims are:
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1) To test the utility of Ct-DNA in capturing ALL tumor heterogeneity at diagnosis.
We compared MAF detected by Ct-DNA analysis of diagnostic PB plasma to
MAF detected by clinical WES of diagnostic BM biopsy sample.
2) To test the utility of Ct-DNA in monitoring the change in clonal dynamics during
remission induction therapy. We compared the results of somatic mutation
detection in Ct-DNA to FC based clinical MRD, with a specific focus on patients
with negative MRD.
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CHAPTER 2. LITERATURE REVIEW

Genetics and Pharmacogenomics in ALL
Introduction
Acute Lymphoblastic Leukemia (ALL) shows the highest prevalence among
children and adolescents in the United States, comprising one fifth of the cancers in
persons aged below 20 years. [1] ALL comprise a malignant clonal proliferation of
lymphoid progenitor cells of the B-cell or T-cell lineage; B-cell lineage (B-ALL) being
the most common.[2, 19]. Recent advances in cytogenetic and molecular techniques
have allowed for the unraveling of the genetic basis of leukemogenesis, clonal evolution
and relapse. Moreover, it allowed for the study of the prognostic significance of those
genetic alterations, thus improving risk stratification and treatment outcome. [20]. ALL,
either B-cell or T-cell, constitute different subtypes, harboring chromosomal alterations
as well as, secondary sequence mutations. [2]. It has been proposed that the genetic
alterations associated with pathogenesis as well as, relapse occur sequentially. Common
inherited genetic variants and less frequently highly penetrant germline mutations
predispose to ALL [2, 19]. It follows that chromosomal alterations, in the form of
aneuploidy, translocations or intrachromosomal re-arrangement occur as an initiating
event. Finally, secondary genetic mutations or structural alterations in in genes involved
in tumor suppression, cell cycle regulation, apoptosis, lymphoid development and
chromatin modification lead to the clinical manifestation of leukemia. [2]
Genetic heterogeneity, plasticity and clonal evolution in response to therapy
further complicates the genetic landscape of leukemia, where in most cases relapse
emerges from a subclone present at diagnosis or moreover, a pre-leukemic clone.
Additionally, pharmacogenomic determinants of toxicity or response affects the outcome.
[3, 5, 21-23]
A number of advancements led to the improvement in the outcome of ALL; the
use of multi-agent chemotherapy, the use of response-adapted therapy where biological
features together with minimal residual disease evaluation are used for patient
stratification, as well as the consideration of pharmacodynamics, pharmacokinetics and
pharmacogenomic features. Despite the unpreceded improvement in the outcome, relapse
still represents a challenge. [5, 24]
Germline Variants Associated with Increased Risk of ALL Development
Inherited susceptibility to ALL occurs through highly penetrant germline
mutations, predisposing to high-risk childhood leukemia in rare familial cases or common
susceptibility alleles, associated with lower risk for leukemia development. [23, 25].
During leukemogenesis, interaction occurs between inherited and somatic genetic
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alterations, where specific inherited alleles predispose to specific chromosomal-defined
subtypes, hence playing a role in disease pathogenesis and prognosis [26] Another
synergistic interaction exists between inherited and acquired genetic alterations, where
somatic mutations target ALL susceptibility loci [27]
Loss of function of mutations in TP53, associated with Li-Fraumeni syndrome,
have been reported in more than 90% of children with low hypodiploid ALL. The
mutations included missense, non-sense as well as, indels mostly in a homozygous state
because of aneuploidy. The presence of TP53 in non-tumor cells in 43% of patients
suggested that the mutation is either inherited or a denovo mutation acquired in germline
or hematopoietic compartment. The inherited origin of TP53 was highly suggested due to
the presence of family history in 2 patients and its confirmation in another patient through
studying non-hematopoietic cells [28].
Mutations of PAX5 show another example of inherited deleterious penetrant
mutations in pediatric ALL [23]. PAX5 is a transcription factor encoding B-cell lineagespecific activator protein (BSAP). The transcriptional control of Pro-B cell development
occurs through both activation of B-cell specific genes (BLNK, Igα, CD19) as well as,
repression of alternate pathway genes (MPO, Notch1, M-CSFR), thus playing a major
role in B-cell commitment and fate. [29, 30]. A number of partner genes are involved;
HIPK1, FOXP1, POM121, ELN, AUTS2, JAK2, ETV6, DACH1, PML, ZNF521, BRD1,
CHFR, SOX5 and POM121C [27, 31, 32]. In 2013, inherited germline mutations of
PAX5 were reported in two kindred of uncommon ancestry. The heterozygous germline
variant affected PAX5 octapeptide domain and resulted in decreased transcriptional
activity. PAX5 mutations were present together with deletion of 9p and loss of
heterozygosity in all the affected children within both families. However, the mutation
showed incomplete penetrance. [23, 29]
Other genes associated with increased susceptibility to ALL, among different
groups, have been identified by GWAS association studies. The top list includes
ARID5B, IKZF1, CEBPE, CDKN2A, PIP4K2A, GATA3 and TP63 [25]. ARID5B (AT
rich interaction domain transcription factor), IKZF1 (Transcriptional regulator of the
differentiation of lymphoid cells) and CEBPE showed significant association with the
risk of ALL, and in addition retained significant association to B-cell ALL. ARID5B was
shown to be associated with an increased risk of development of hyperdiploid ALL. [3335]. CDKN2A encodes both p16 (INK4A) which negatively regulates cyclin-dependent
kinases, as well as p14 (ARF1), an activator of p53. rs3731217 which localizes to intron
1 of CDKN2A showed significant association with both B-cell and T-cell ALL. [36].
However, ARID5B, IKZF1, CEBPE, CDKN2A altogether, underscore for 8% of B-cell
precursor genetic variance. [37]. PIP4K2 belongs to a family of enzymes which
phosphorylates phosphatidylinositol-5-phosphate to form phosphatidylinositol-5,4bisphosphate (PIP2), a PIP3 precursor. The clustering of four SNPs within PIP4K2A
gene intronic region was reported; with rs10828317 showing specific association with
hyperdiploid ALL. [38, 39] TP63 (a member of TP53 family) and PTPRJ (Protein
Tyrosine Phosphatase, Receptor Type J, involved in the regulation of several cellular
processes including cell differentiation, cell growth, mitotic cell cycle as well as,
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oncogenic transformation) have been identified as susceptibility genes to ETV6-RUNX1rearranged pediatric ALL. [35].
Several studies have addressed the association between GATA3 (a transcription
factor and putative tumor suppressor gene) and genetic susceptibility to B-cell leukemia.
GATA3 rs3824662, which maps to a predicted enhancer, showed association with non(Tel-AML) positive, non-hyperdiploid ALL. rs3824662 homozygous risk allele showed a
significant correlation to older age as well as, worse event free survival [39]. In a
discovery GWAS in adolescents and young adult patients, the frequency of GATA3 risk
allele was higher in patients aged 16yrs or above, compared to younger patients
irrespective of the subtype. [40] In a GWAS of Ph-like ALL, rs3824662 allele showed
strong association with Ph-like associated genetic lesions (JAK mutation, CRLF2
rearrangement, and IKZF1 deletion). [26]. Additionally, rs3824662 A allele was
associated with an increased risk of relapse, as well as higher level of MRD measured at
end of induction. Compared to non-ALL controls, rs3824662 was also overrepresented in
non-Ph-like-ALL implying a variant effect on ALL predisposition in general. [26].
Recurrent Somatic Genetic Alterations of Precursor B-cell ALL (BCP-ALL)
Chromosomal alterations include aneuploidy, chromosomal rearrangements, and
translocations [19]. Translocations either relocates oncogenes under the effect of
regulatory regions of actively transcribed genes; hence leading to the dysregulated
expression of the oncogenic protein or fuses two genes resulting in the expression of a
chimeric functionally distinct protein. Several subtypes of ALL, lacking a single
characterizing chromosomal alteration, have been characterized based on genomic (i.e.
unique gene expression profile) or pathologic features. [2] Advancements in NGS and
array-based cytogenetic techniques have allowed for the discovery of submicroscopic
DNA alterations in genes involved in various cellular processes i.e. normal
hematopoiesis, cell cycle regulation, tumor suppression and apoptosis. In addition, it
allowed for a deeper insight into the known recurrent abnormalities, as well as the
unraveling of gene targets involved in abnormal hematopoiesis and relapse. [20]
Aneuploidy. Aneuploidy is further classifier into the following:
High hyperdiploid ALL. defined as 51-65 chromosomes, confers good prognosis
in 25-30% of BCP pediatric ALL. [20, 41] High hyperdiploid ALL genomic landscape
showed involvement of histone modifiers and RTK-RAS pathway. Structural alterations
included structural deletions, duplications, translocations, as well as complex
rearrangements of a number of genes including ETV6, IKZF1, PAX5 and ADD3. Single
nucleotide variations in the form of substitutions and indels were detected in nine genes
including FLT3, KRAS, NRAS, WHSC1, CREBBP, and PTPN11, known to be associated
with leukemia. [42]
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Hypodiploid ALL. defined as less or equal 45 chromosomes, represents 6-7% of
pediatric ALL. [43] Hypodiploid ALL is further classified into subgroups; namely high
hypodiploid (40-43 chromosomes), low-hypodiploid (32–39 chromosomes) and nearhaploid (24-31 chromosome) [44]. The first genomic analysis done to characterize
hypodiploid leukemia has shown that near-haploid and low-hypodiploid show
recognizably different sequence mutations and focal deletions, hence compromising two
distinct subtypes. Near haploid ALL, harbored deletion in PAG1 (Csk-binding protein
(CBP)), deletion of the lymphoid transcription factor gene IKZF3, deletions of a histone
cluster at chromosome 6p22, activating genetic alteration (deletion, amplification and/or
sequence mutation) affecting the RTK or RAS signaling pathway (of NF1, NRAS, KRAS,
MAPK1, FLT3 or PTPN11 genes), RB1 alterations. Low-hypodiploid cases, however,
showed TP53 sequence mutations (nonsense, missense and indels) in 88.2, IKZF2
deletion, RB1 alteration. [28].
Recurrent translocations of pediatric BCP-ALL. Translocations arise from
either the fusion of two genes or the relocation of an oncogene into a regulatory region of
another active gene. This results in the production of a new chimeric protein with a
recognizably different function from the joined genes or the dysregulation of expression
of an oncogene, respectively. [2]
Common translocations of BCP ALL include ETV6-RUNX1 (TEL-AML1),
TCF3-PBX1 (E2A-PBX1), BCR-ABL1 (Philadelphia chromosome), MLL gene
rearrangements, IGH translocations and Intrachromosomal amplification of chromosome
21 (iAMP21). Various translocations exist at different frequencies among different age
and ethnic groups. [23].
Recurrent genetic alterations of pediatric T-cell ALL. T-cell ALL can be
subclassified into three groups: (1) Early T-cell precursor (ETP), (2) Near-ETP ALL and
(3) Non-ETP ALL. Detailed characteristics of ETP are discussed in the following
section. T-cell ALL is associated with dysregulation of the expression of transcription
factor genes. Such dysregulation can be employed to classify T-cell ALL into 8 groups
according to the deregulated gene (TAL1, TAL2, TLX1, TLX3, HOXA, LMO1/LMO2,
LMO2/LYL1 and NKX2-1). TAL1 deregulation frequently occurs in both near- and
non-ETP ALL; whereas TLX3 is more frequently detected in near-ETP cases, and
deregulation of TLX1 deregulation showed to be the most common non-ETP ALL. [45]
New ALL subtypes. The newly discovered genetic alterations have a clinical
implication on the diagnosis, risk assignment as well as, targeted therapy. [20] New ALL
subtypes include Philadelphia chromosome-like ALL, Early T-cell precursor (ETP) ALL,
DUX4-, and ERG-Deregulated ALL, and MEF2D, and ZNF384 gene fusions. [19]
Philadelphia chromosome-like ALL (BCR-ABL1-like ALL. BCR-ABL1-like
ALL occurs at a higher frequency in young adults (27% vs 10% in children). This
comprises a group of patients who possess leukemia cell gene expression profile similar
to that of Ph-positive ALL, despite the lack of BCR-ABL1 fusion. However, the majority
of patients in this group carries genetic alterations activating the kinase signaling
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pathways. The most common genetic alterations detections are rearrangements in ABL1,
ABL2, CRLF2, PDGFRB, PTK2B, TSLP, TYK2, CSF1R, EPOR, NTRK3, JAK2, and
sequence mutations in FLT3, IL7R, or SH2B3. [23, 27, 46, 47]
Early T-cell precursor (ETP) ALL. ETP ALL Early T-cell precursor (ETP)
represents 15% of T-cell ALL and is associated with poor outcome. ETP comprises a
distinct entity of leukemia, with a characteristic pattern of gene expression different from
human early T-cell precursor cells. ETP ALL expresses myeloid or stem cell markers.
Additionally, the gene expression profile of ETP ALL showed enrichment for signatures
associated with poor outcome ALL (leukemic stem-cell signature, IKZF1-mutated highrisk B-progenitor ALL signature). [19, 48, 49]. ETP ALL commonly demonstrates
dysregulation in the expression of transcription factor genes LMO2/LYL1 [45]
Genes frequently mutated in ETP ALL comprise RAS signaling pathways,
cytokine receptor regulation, epigenetic regulation and hematopoietic development.
Activating mutations in genes involved in RAS signaling and cytokine receptor
regulation (KRAS, NRAS, IL7R, FLT3, BRAF, JAK1, JAK3 and SH2B3) exist at the
highest frequency. Genes harboring mutations that inactivate hematopoietic development
include ETV6, RUNX1, IKZF, GATA3, and EP300 whereas histone modifying genes
affected include SETD2, EZH2, EED, SUZ12, and EP300. [19, 48]
Pathways Commonly Mutated in Pediatric ALL
Pathways commonly mutated in B-cell precursor ALL at diagnosis. In a study
of clonal evolution of pediatric B-cell leukemia from diagnosis to relapse, high frequency
of mutations was detected in six pathways at diagnosis and/or relapse. Different mutation
frequency existed among different pathways; epigenetic modification (65%), Ras
signaling (65%), JAK-STAT signaling, (25%), transcriptional regulation of lymphoid
development (85%), nucleoside metabolism (45%), and cell cycle regulation (60%). In
addition, NT5C2, CREBBP, WHSC1, TP53, USH2A, NRAS and IKZF1 mutations have
shown to be enriched at relapse [3].
Pathways commonly mutated in T-cell ALL at diagnosis. In T-cell, ten
pathways were recurrently mutated. As is the case with BCP, transcriptional regulation
showed the highest mutation frequency (91%). Other pathways that showed recurrent
mutations were cell cycle regulation and tumor suppression in 84% of the studied case,
NOTCH1 signaling in 79%, epigenetic modification in 68% and to lesser extent JAKSTAT signaling (25%), PI3K-AKT-mTOR signaling (29%), ribosomal function (13%),
RNA processing (9%) whereas RAS signaling was only mutated in 14% of the cases.
[45]
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Somatic Mutations Associated with Relapse and Therapy Resistance
Mutation frequency has been shown to vary among different subtypes in relation
to enrichment at diagnosis or relapse. Moreover, a number of studies have unraveled the
association between specific mutations and therapy resistance. Importantly, the cytotoxic
activity of novel small molecules in mutant cells has been shown, holding promise for
future role in the clinic. Moreover, reversal of the resistant phenotype and regaining of
sensitivity was demonstrated. [11, 50]
Several studies have addressed somatic mutations in epigenetic regulators in high
risk groups of leukemia, however, the reported frequency varies in different subtypes of
denovo ALL. 60% of hypodiploid cases carried somatic mutations in genes encoding
epigenetic regulators. In contrast to other ALL subtypes where CREBPP is more enriched
in relapse, mutation in CREBPP was the most common epigenetic regulator mutation
reported in denovo hypodiploid ALL. CREBBP encodes a histone/non-histone
acetyltransferases which plays a role in regulation of glucocorticoid gene expression, its
mutation contributes to prednisolone/dexamethasone (glucocorticoid) resistance [9, 51];
[28] CREBBP mutations were also prevalent among hyperdiploid ALL relapsed cases.
[52]. Missense mutations were also detected in EZF2 gene; with 2 cases harboring EZF2
mutations only at relapse [3, 48].
Matched diagnosis/remission/relapse samples of pediatric patients with B-cell
ALL showed enrichment of mutations in genes coding epigenetic regulators at relapse,
with 57% of the patients harboring epigenetic regulator mutations at relapse. Frequently
mutated epigenetic regulators included MLL2, KDM6A and MSH6, as well as additional
mutations in SETD2 and CREBBP. The high frequency of mutations detected in relapsed
cases, as well as denovo high risk ALL, plus the different mechanisms by which SETD2
and MSH6 can promote clonal survival, explains a possible role in chemotherapy
resistance. The importance of such findings lies in the possible future role of epigenetic
therapy aiming at inhibiting the enzymatic activity of the opposing regulators [53].
Another study also showed a relapse mutation rate in epigenetic regulator genes of 65%
compared to 45% at diagnosis; with relapse-specific mutations found in WHSC1 and
CREBBP; with CREBBP showing multiclonal mutations in one case [3].
In a group of patients with ETP, 48% showed activating mutations in histone
modifying genes, namely EZH2, EED, SUZ12, SETD2 and EP300 [28, 48]. Also,
Mutations in WHSC1, SUZ12, SMARCA4, ARID4B and USP7 were reported as relapse
specific mutations in T-cell ALL pediatric patients. A finding that highlights the
importance of somatic mutations in epigenetic regulators is the detection of E1099K
activating mutation in the H3K36 histone methyl transferase (WHSC1) as the only
mutational difference between primary leukemia and relapse in a patient who suffered
early relapse [7].
Several studies have reported RAS mutations to be subclonal, with a
heterogeneous pattern of clonal evolution; where associated RAS mutations can be
gained, lost or even retained from diagnosis to relapse. [3, 54] In BCP ALL, RAS
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mutations (KRAS, NRAS, FLT3, PTPN11 were highly prevalent (Incidence 37.9%) at
relapse, and more importantly, demonstrated significant association with early relapse
(KRAS/NRAS), as well as CNS involvement [50] The role of RAS-MAPK signaling in
drug resistance has been studied both in human cell lines as well as, mouse primary
isogenic leukemic lymphoblasts. Functional analysis of RAS mutations corroborates a
role of this signaling pathway in methotrexate resistance; as well as increased sensitivity
to vincristine. Thus, positive or negative selection of RAS mutant clones can occur at
relapse. [54].
In vitro functional analysis as well as, genetic study of T-cell ALL reported an
association between IL-7receptor signaling components (including KRAS and JAK-1)
and poor prednisone response and clinical outcome. [55]. An important
pharmacogenomic implication to that association, is the finding that combining
ruxolitinib, a JAK1/2 inhibitor, and dexamethasone may enhance the efficacy of
glucocorticoids (GC) in a subset of T-cell ALL, with IL-7 dependent GC resistance. [56]
Multiple relapse-specific activating mutations in NT5C2, conferring resistance to
purine analogues (6-MP and TG), have been discovered in both BCP and T-cell. NT5C2
encodes a hydrolase which metabolizes and inactivates active metabolites of 6-MP, hence
affecting 6-MP cytotoxicity. Several groups demonstrated NT5C2 to be exclusively
present in relapse samples. However, the frequency of NT5C2 varied across different
studies from 3%-45% in BCP [3, 57] . Ma et al. detected NT5C2 at 45% in relapse cases,
with 3 cases showing multiclonal mutations whereas, in 4 out of 14 cases, mutations at
relapse were subclonal from the relapse founder clone. [3]. NT5C2 demonstrated a
significant association with early relapse (within 36 months of diagnosis). In was
detected at a frequency of 16% in early relapsing patients and 100% of Individuals
carrying NT5C2 mutations encountered early relapse [6].
In T-cell pediatric patients, NT5C2 was among the most common relapse
mutations, detected at a frequency 19%-38.5% across different studies [7, 57]. As is the
case in BCP, NT5C2 could be present as clonal or subclonal mutation at relapse, hence
representing a late event in relapse. [7]
Mutually exclusive to NT5C2, multiple activating PRPS1 mutations have been
identified as relapse specific in B-cell pediatric ALL. PRSP1 mutants modulate
thiopurine activity indirectly through reduced feedback inhibition of de novo purine
synthesis and hence, competitive inhibition of thiopurine activation. Mutant PRSPS1
conferred early relapse in all patients who carried the mutation. Other relapse specific
mutations in the denovo purine synthesis pathway have been detected; involving PRPS2,
ATIC, ADSL, GART and PFAS. [11]
Tumor Heterogeneity, Clonal Evolution and Therapy Resistance
The notion that tumors are formed of evolving clones predicts specific
characteristics: the presence of clonal genotypes, the temporal change in clonal dynamics,
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spatial variation across different sites, emergence of drug resistant clones, partial
response to drug therapy, as well as relapse originating from minor subclones. [3, 58, 59]
Generally, ALL is polyclonal at diagnosis i.e. multiple genetically distinct clones,
sharing the common clonal origin are present at diagnosis. It has been shown that 50% of
the BCP ALL cases leukemias exhibit multiple subclonal mutations at diagnosis.
Different subclones show various response to the selective pressure imposed by therapy
[2, 3, 60]. It has been assumed that therapy exerts its effect on clonal evolution via one of
three. The first model “Differential Sensitivity” model, in which active selection of
therapy resistant clones takes place, resulting in convergent evolution, in which the drug
resistant mutation become the predominant clone at relapse. Differential sensitivity
model may show specific relevance to targeted therapies directed against genetic
alterations not shared across various clones. [10]. The second “Mass Extinction and
Competitive Release” model, assumes equal therapy sensitivity across various subclones,
as evident by comparable proportion pre-and post cytoreduction. In this second model,
the evolutionary landscape is continuously altered by the clearing niche, causing the best
fitting clone to expand. [10, 61]. The third model is “Chemotherapy Induced
Mutagenesis”, where novel mutations are induced by genotoxic chemotherapy [10]. The
last model is less likely to explain clonal evolution in pediatric ALL as current treatment
protocols limit the use of mutagenic agents and there is no shift in mutation burden nor an
increase in the burden of sequence mutations. [3]
A recent study of the mutational profiling in two ALL kids with testicular relapse
has shown that in one case (combined BM and testicular relapse), the relapse clone
evolved from an ancestral clone. Importantly, the VAF analysis showed that although
BM and testicular leukemia originate from the ancestral clone, yet the testicular relapse
represents an independent subclone (that shares a fraction of mutations with the
diagnostic clone which were absent in the marrow). [12]
In most cases, a minor subclone at diagnosis that either harbors or acquires
additional mutations conferring therapy resistance or else from ancestral clones
(premalignant clone) prior to the dominant diagnostic clone, survives therapy and
expands to be the relapse founder clone. To a lesser extent, predominant relapse clones
are identical to or genetically distinct from the diagnostic clones representing a secondary
leukemia. [2, 3, 5, 60]. Hence, a better understanding of clonal evolution, drug resistance
mechanisms is required, in order to tailor therapy in a way that counters clonal evolution,
consequently improving the outcome. [58].
Clinical Implications of Monitoring Clonal Dynamics and Drug Resistance
Backtracking of serial BM samples in relapsing ALL patients harboring PRSP1
mutation, conferring resistance to purine analogues, showed an exponential increase in
the percentage of PRSP1 mutation, prior to clinical relapse. NT5C2 was also detected in a
remission prior to clinical relapse. [11]
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The detection of somatic mutations has a great role in advancing precision
medicine. Ruxolitinib, a JAK1 inhibitor, has been incorporated in a recent clinical trial
for patients harboring genetic alterations (mutations, deletions or re-arrangements)
affecting the JAK/STAT signaling (e.g., EPOR, IL7R, JAK1, JAK2, JAK3 or SH2B3).
(unpublished data) Studies on small molecules also hold a great promise in combating
resistance associated with specific pathways. Selumetinib, an allosteric selective 1/2
MEK-inhibitor, demonstrated significant in vitro cytotoxicity against RAS-mutant ALL
cells harboring KRAS, G12D and G13D or NRAS, Q61R. Moreover, it showed
significant decrease in the level of circulating blasts in mice xenografted with RASmutant primary ALL cells harboring KRAS, G12D or NRAS, Q61R; as well as
significantly decreased the CNS disease burden. MEK inhibitors may carry a therapeutic
role in the future in patients harboring RAS mutations. [50] Lometrexol, GART inhibitor,
provides another example; it successfully inhibited denovo purine synthesis resulting in
reversal of thiopurine resistance in PRPS1 mutant cells[11].
Not only small molecules show promising activity, conventional chemotherapy
might still play a role in patients harboring mutations to as specific drug; i.e. in patients
with NT5C2 mutations, the mutation didn’t confer resistance to Nelarabine, used as
second line therapy in T-cell ALL. (T-cell). [57]
Pharmacogenomics of ALL
In addition to the aforementioned genetic alterations; several germline variants
play a role as pharmacogenomic determinants of toxicity or drug response affecting the
treatment outcome.
Germline variants associated with poor outcome. In a Genome-wide
association (GWAS) studying the relationship between genotypes at single nucleotide
polymorphisms and risk of relapse, 134 SNPs were found to be associated with relapse.
133 SNPs showed to be prognostic after adjusting for other risk factors. Top 25 SNPs
associated with ALL relapse involved the following genes PYGL, MYRIP, LOC642340,
PDE4B, TBXAS1, MAGI2, RIT2, NPFFR1, ATP8A2, PDE4B, ANTXR1, NPAS3,
ATP8A2, STAG1, ANKS1B, ATP8A2 (validation frequency ranging between 37%79%). [62]
One important finding of the study is the significant association between relapseassociated SNPs and pharmacokinetics and pharmacodynamics of 3 antileukemic drugs
(L-asparaginase, dexamethasone and methotrexate) as follows: 2 relapse specific SNPs
within FCHSD1 gene showed association with high L-asparaginase antibody levels and
increased risk of relapse, 4 SNPs (2 in ABCB1 gene) showed an association with higher
dexamethasone clearance, 5 SNPs (3 SNPs within the PDE4B gene) showed association
with lower intracellular methotrexate polyglumate accumulation, as well as 3 SNPs
associated with higher MTX clearance. The role ABCB1 (MDR1) in the transport of
other chemotherapeutic agents (glucocorticoids, anthracyclines and vincristine), raises the
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possibility that the association between ABCB1 SNP and outcome is due to unfavorable
host pharmacokinetic properties as well as, intrinsic leukemic blast resistance [62]
Germline SNPs associated with increased toxicity to antileukemic therapy
SNPs associated with Vincristine toxicity. Several studies evaluated the
association of SNPs to Vincristine peripheral neuropathy. A CEP72 variant is associated
with increased vincristine neuropathy during maintenance therapy in pediatric ALL
patients treated with 1.5 mg/m2 vincristine. The mutant protein (T allele at rs924607)
increases sensitivity to vincristine through binding a transcription repressor, leading to
lower level of CEP72 expression. Patients homozygous for the risk allele showed a
significant increase in the cumulate incidence of Grade 3-4 neuropathy. [63]. CEP72
polymorphism was not related to the incidence of neuropathy during or by the end of
remission induction in the same patient cohort. [64]. Polymorphisms in drug transporter
ABCC2 may play a role in vincristine neuropathy during induction, where 3 SNPs were
shown to associated with neurotoxicity in early phases of treatment in the primary
analysis yet didn’t reach statistical significance after FDR correction. [65]. A higher risk
of high grade neurotoxicity was associated with one SNP in the ACTG1 gene, which
encodes a major cytoskeletal protein ACTG. 2 SNPs in CAPG and ABCB1 genes were
shown to be protective against low grade neurotoxicity. [66]
SNPs associated with 6-Mercaptopurine toxicity. The relationship between
TPMT genetic variation and thiopurine toxicities has been well established and
preemptive TPMT genotyping is used clinically to guide MP dosing during ALL therapy
[67]. Despite the reduction in toxicity brought about by preemptive TPMT-guided dosing,
clinically significant thiopurine-related myelosuppression is still observed in patients
with so-called normal TPMT activity. [68]
Several recent studies addressed the association between genetic variants other
than TPMT and 6MP toxicities. In the discovery GWAS of 657 children with ALL in the
AALL03N1 cohort, a germline variant in NUDT15 (rs116855232) strongly associated
with MP dose intensity in childhood ALL (P = 8.8 x 10-9), where the number of copies of
the T allele at the NUDT15 SNP rs116855232 showed a significant correlation with
tolerated MP dose, indicating a gene dosage effect. Patients heterozygous for NUDT15
variants (TC genotype) tolerate 63% of a standard 6-MP dose and NUDT15-deficient
patients (TT genotype) tolerated only 8% of a standard dose. Yang et al. also showed that
rs116855232 genotype distribution varied substantially by race/ethnicity, being more
frequent in East Asians (9.8%). Consistent with these findings Tanaka et al. 2015 showed
a statistically significant NUDT15 association with grade 3-4 leucopenia development
within 60 days of the initiation of maintenance therapy (early leucopenia) in a cohort of
92 Japanese children with acute lymphoblastic leukemia. Although both TPMT and
NUDT15 are associated with susceptibility to 6-MP toxicity, different mechanisms are
hypothesized. [68] For TPMT, the risk variants affect metabolism leading to
accumulation of TGNs, the active metabolite of 6-MP, in hematopoietic tissues while for
NUDT15, susceptibility to toxicity involves DNA repair and apoptotic pathways.[69]
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Mutation in ABCC4 (rs3765534), a drug efflux transporter, showed significant
association with severe neutropenia in Japanese patients with childhood leukemia. The
combined effect of ABCC4 and heterozygous NUDT15 variants was similar to that
conferred by loss of NUDT15 activity. [70]
SNPs associated with L-Asparaginase toxicity. A recent GWAS study detected
an association between germline mutations in ULK2, a gene involved in autophagy as
well as, in RGS6 gene (a negative regulator of G-protein signaling) and asparaginase
associated pancreatitis (AAP). In patients <10 years, heterozygous for both risk alleles
(ULK2 rs281366 and RGS6 rs17179470) showed AAP cumulative incidence of 85%,
compared to 22.5% in patients harboring only one risk allele, whereas the incidence in
patients without no risk allele was 4.1%. [71]
Few studies addressed associations between SNPs and L-asparaginase
hypersensitivity. Asparaginase allergy was significantly associated with GRIA1 variants
(rs10070447, rs6890057, rs4958676, and rs6889909) [72], HLA-DRB1*07:01 allele
(45% higher incidence of L-asparaginase hypersensitivity) [73] and intronic
polymorphism in NFATC2 (rs6021191). It has also been shown that patients carrying
both NFATC2 rs6021191 and HLA-DRB1rs17885382 variants are at higher risk of
developing asparaginase hypersensitivity compared with patients with single or no risk
alleles [74]
SNPs associated with methotrexate toxicity. The most common toxicities
following MTX administration are nephrotoxicity, hepatotoxicity and myelosuppression.
Several genetic polymorphisms showed association with a specific MTX toxicity.
Polymorphisms of the ARID5B gene (rs4948502, rs4948496, rs4948487) were associated
with MTX and 7-OH-MTX serum levels, and toxicity. SLC19A1 rs7499 was
significantly associated with hepatotoxicity; yet SLC9A1 rs1051266 didn’t show
correlation with toxicity. Granulocytopenia post 2gm/m2 MTX dose was associated with
MTR rs3768142 [75]. SLCO1B1 also shows association MTX pharmacokinetics. [76]
Monitoring Disease Response in Pediatric Leukemia
Introduction
In leukemia patients, minimal residual disease (MRD) represents leukemic cells
undetectable by morphologic examination of bone marrow smears. Acute lymphoblastic
leukemia (ALL) has been at the head of the development of MRD methods.[77] Testing
of MRD has a great impact on the advancement of ALL treatment; it has shaped the
definition of remission, proved to be the most important prognostic factor for treatment
outcome and it measure during induction , as well as at specific points throughout
therapy, has been used to risk-stratify the patients according to treatment response [4, 15]
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Detection of Minimal Residual Disease (MRD) in Pediatric ALL
Sampling. An important point to consider, when looking into the reliability of
MRD measurement in representing the burden of the disease, is that studies are
performed on a single small bone marrow aliquot, assuming heterogeneity throughout the
marrow. In fact, it has been shown as early as 1966 that heterogeneity is associated with
the distribution of leukemia, where 38% of patients who were morphologically in
remission by peripheral blood and single bone marrow samples had persistent infiltration
in different site. [78, 79]
Analytical platforms for MRD measurement. Currently applied methods for
measuring MRD in lymphoblastic leukemia are based on specific molecular and cellular
characteristics [80] Each of the mentioned techniques is associated with advantages and
limitations.
Flow Cytometry (FC). Leukemic blasts differ immunophenotypically from
normal cells, as they express abnormal cell markers, hence flow cytometry can be used to
detect leukemic lymphoblasts (based on the cell markers) with a limit of detection of
0.01% (1leukemic cell in 10,000 normal cells). [79, 81] The advantages of Flow
cytometry are the accuracy of detection, ability to detect the hematopoietic cell
maturation, easy storage of data and less time and labor needed compared to PCR. [15,
82]
However, a number of limitations do exist. Flow cytometry is based on the
phenotypic markers of the diagnostic dominant clone [16], the sensitivity is compromised
by the difficulty inherited in the differentiation between ALL clones and regenerating
blasts and importantly, it lacks the ability to detect emerging clones, that differ
phenotypically from the diagnostic clone i.e. it doesn’t take into consideration the
phenotype alteration associated with therapy derived clonal evolution. [15, 16, 82]
Polymerase Chain Reaction (PCR). PCR is applied to detect either
rearrangement of T-cell receptor (TCR) and immunoglobulin (IG), which can be
measured at a sensitivity of 0.001% by PCR. [83] the presence of chromosomal
alterations (PCR amplification of fusion transcripts) [84]
Detection of TCR and IG re-arrangement by PCR shows high sensitivity and
applicability in 90-95% of the patients. Moreover, in one study, it was shown to better
predict T-cell leukemia patients with high risk of relapse than does flow cytometry[85].
As is the case with flow cytometry, the inability to detect subclones (due to the use of
specific primer sets for the dominant clone) represents a major drawback. [15, 16]
Additionally, PCR is associated with more time and labor due to the design of patient
specific primer sets.[79]
A main advantage of the fusion transcripts amplification is that gene fusions,
being early initiating events, exist in stable association with the leukemic clone,
regardless of clonal selection. On the other side, drawbacks are the inaccurate
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quantification due to intra-patient variability in the number of fusion transcripts per
leukemic cell as well as, interpatient variability throughout treatment duration, and
existence in less than half of leukemia patients. [3]
Next Generation Sequencing (NGS). Next generation sequencing is based on the
use of consensus primers for parallel rapid sequencing. NGS overcomes a number of
disadvantages associated with PCR. NGS is associated with higher sensitivity compared
to PCR (up to 1 E06), the use of consensus primer rather than patient specific primers
decreased the time and labor associated with the test, the ability to quantitate clonal
evolution, hence allowing a deeper insight into the biology of leukemia as well as, the
kinetics of relapse. The challenges associated with NGS is the need for the presence of
high frequency index clone in the initial diagnostic sample and the expertise needed to
use complex bioinformatics approaches in the analysis. [15, 16, 86, 87]
Somatic Mutation Detection in Leukemia-derived Circulating DNA
Introduction
Tumor heterogeneity, spatial and temporal, has been documented in cancer
patients including pediatric ALL [3, 7, 12]. Therapy exerts a selective pressure leading to
clonal evolution and therapy resistance [6, 10, 12]. Hence, one of the greatest challenge,
for precision medicine, is to overcome tumor heterogeneity [88] , consequently
improving the outcome.
Comprehensive characterization of the disease has been limited by sampling and
technical issues incorporated in disease follow-up. Limitations associated with sampling
include: single site biopsies lack the ability to capture heterogeneity among spatially
separated malignant clones [14], the invasiveness of the procedures used limits the ability
to obtain serial samples hence, the detection of the change mutational landscape
throughout treatment [18] , the sufficiency of the sample to perform multiple assays [88]
and quality of the specimens, i.e. BM hypoplasia or fibrosis can lead to low quality
samples in MDS patients [17]. The criteria used to evaluate the disease, lack the ability to
detect the change in the dynamics of the evolving malignant clones [17].
Ct-DNA analysis serves a minimally invasive technique, which can be repeated at
multiple time points, comprehensively characterize contributions from heterogeneous
clones [88]. and capture the differential response of different disease subclones
throughout therapy and predict disease progression [17]. Moreover, the discovery of
actionable mutations in Ct-DNA has potential important implications in the advancement
of precision medicine. [14]
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Characteristics of Cell-free and Circulating-tumor DNA
As early as 1948, Mendel and Mètais were the first to describe cell-free DNA (CfDNA); fragments of DNA circulating freely in plasma. [89-91]. The detection of
circulating DNA in the plasma of cancer patients occurred later, in 1987, when M. Stroun
et al. isolated an extractable quantity of DNA from 27% of studied cancer patients as
compared to none in normal controls, as well as, confirmed the human origin of the
isolated DNA.[92]
Using murine models xenografted with human derived tumors, human derived
circulating DNA was detected in the plasma of mice, along with an increased level of
mouse derived DNA, demonstrating that CF-DNA is derived from both normal and
tumor cells. [93]. The exact mechanism of release of circulating DNA into the plasma of
cancer patients requires further elucidation. [94] Several mechanisms have been
demonstrated mainly; apoptosis, necrosis, in addition to active secretion. [95] Apoptosis
leads to the generation of fragments with size 180 bp or multiples, whereas necrosis
produces much larger fragments. It has, hence, been suggested that different sizes of
DNA fragments can be applied to distinguish between apoptosis and necrosis as sources
of circulating DNA [96] However, studies demonstrated that 90% out of the total
circulating DNA exist in a size range of 150-180bp [89] with a significant peak at 166 bp,
representing a mono-nucleosome DNA length (147 bp) plus the length of the Histone H1
linker DNA (20bp) [97]
The kinetic properties of Cf-DNA clearance have been derived from the studying
of fetal Cf-DNA clearance from maternal plasma. The clearance of Cf-DNA occurs in
two phases [98, 99], an initial rapid phase (mean half-life 1 hr.) corresponding to
distribution/elimination followed by a second slower phase (mean half-life 13 hr.)
corresponding to total elimination. [98, 100] It was also shown that several mechanisms
contribute to clearance; with DNAse and trans-renal eliminations playing a minor role.
[97, 98, 101]
It has been demonstrated that the change in circulating DNA level is correlated to
treatment response after radiation therapy i.e. persistence of circulating DNA is
associated with a poor treatment response whereas a decrease in the level of circulating
DNA is associated with radiological signs of remission in different solid tumors. [102]
Years later, it was shown, through the advancement of molecular techniques, that
circulating nucleic acid displays a wide range of tumor-associated genetic alterations i.e.
chromosomal alterations (Inversions & deletions), microsatellite alterations, point
mutations, microsatellite alterations as well as, promotor hypermethylation. [10, 103]
These finding, opened the door for studying the utility of Ct-DNA analysis in a wide
range of applications in various tumor types.
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Pre-analytical Considerations Affecting Cf-DNA Analysis
The variability in the levels of Cf-DNA detected across different studies can be
attributed not only to the biological variability between patients, but also to the origins of
contaminating DNA as well as, the sensitivity of the analysis methods. Hence, it is
crucial to consider the pre-analytical factors that affect the stability and yield of Cf-DNA
as well as, those that minimize contamination from other sources of DNA (i.e. genomic
DNA). [89]
Blood sampling. Plasma was shown to be a better matrix compared to serum for
studying Ct-DNA. It has been shown that the increased concentration of Cf-DNA in
serum occurs due to clotting of WBCs and release of genomic DNA which contributes to
the higher concentration of Cf-DNA in serum. [104] It has also been demonstrated that
plasma is a better source for study tumor derived Cf-DNA. In mice xenografted with
CRC cells, Thierry et al. were able to show that a higher concentration of Cf-DNA was
detected in serum, as compared to plasma, when using murine specific KRAS wild-type
primers. On the contrary, using human wild-type KRAS primers (targeting tumor derived
Cf-DNA), the concentration measured was higher in plasma; indicating that plasma
serves as a more reliable source for studying tumor derived Cf-DNA. [100, 105]
Anticoagulants. Lam et al. studied the effect of different anticoagulants on the
concentration of Cf-DNA using quantitative real-time PCR. They showed that no
significant difference in the concentration of Cf-DNA detected using heparin, citrate and
EDTA as an anticoagulant as long as when plasma separation is done within 6 hr. from
blood collection (P >0.05, Friedman test). However, after 24 hr., EDTA produced higher
Cf-DNA concentration, compared to citrate or heparin. Hence, the authors recommend
EDTA as the anticoagulant of choice if samples are to be stored for 24 hr. before analysis
and considers all the three anticoagulants as acceptable options. [100, 106]
On the other hand, others recommend against the use of heparin as it might inhibit
the polymerase chain reaction of downstream applications. [107] This later result was
confirmed by Ginkel et al., reporting that the concentration of Cf-DNA concentrations
can remain stable in EDTA plasma over 24 hr. until fractionation. [108]
Another study was able to detect a significantly higher concentration in EDTA compared
to heparin at 0 and 3 hr. (P<0.05). [109]
Handling of blood samples. The length of time and temperature of storage of
plasma has been studied. Lam et al. showed that the total concentration of Cf-DNA
increases after 24 hr. compared to the concentration at 0hr and 6 hr, irrespective of the
anticoagulant used, likely due to apoptosis or necrosis of leucocytes. [106]
Cf-DNA quantification. Fluorospectroscopy and fluormetry quantification
methods are used to measure isolated Cf-DNA. Mauger et al. studied the correlation
between the Cf-DNA quantification carried by Nanodrop, Qubit to ddPCR
measurements. They were able to demonstrate a significant strong correlation between
the measurement obtained from Qubit show a significant strong correlation to the
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measurements obtained by ddPCR. On the contrary, Nanodrop measurements lacked
correlation with ddPCR measurements. Hence, the authors the recommend the use of
low-cost Qubit quantification, to confirm that sufficient amount of DNA is isolated, prior
to proceeding to PCR analysis. [109]
Technological Platforms Used in Circulating-tumor DNA (Ct-DNA) Analysis
Introduction. Advancements in the molecular techniques and sequencing
methods have allowed for an upsurge of studies of a wide range of applications of tumor
derived Cf-DNA in various adult and pediatric cancers. [14, 17, 18]. Analysis of tumor
derived Cf-DNA allows for the detection of the entire spectrum of tumor genetic
alterations. The analysis of tumor derived Cf-DNA, however, is complicated by the low
amount present in plasma (especially with low disease burden), the presence of nontumor derived CF-DNA in the plasma, the high degradation and additionally the tumor
heterogeneity. Hence, sensitive detection techniques and analysis pipelines are needed.
[89]
The detection of genetic alterations in Ct-DNA implies two main approaches;
methods with a capability to detect all possible alteration and those targeting specific
changes. [89]
Targeted approaches. The selection of targeted approaches for tumor derived
CF-DNA analysis requires previous knowledge of hotspot mutations (specific positions at
which mutations concentrate) and genetic alterations (indels and mutations). [89]
Digital Droplet PCR. Digital PCR, first described by Vogelstein et al., is based on
mutation analysis by fluorescent probes. [110] The technique involves pairing digital
PCR to Nanoliter-sized droplet technology where the PCR reaction is partitioned into
10,000 to 20,000 independent polymerase reactions per tube, eliminating the error
associated with reverse transcription and normalization. [111] ddPCR is associated with
higher precision and less variability when compared to real-time PCR. [112] The
technique is associated with increased sensitivity, limit of detection as low as 1 in 10,000
copies (0.01%). [111], ddPCR can be applied in SNV, CNV analysis, rare variants
detections and quantification of transcripts. [113] It has been implied in the analysis of
Ct-DNA in a wide range of cancers as well as, for the validation of other methods used
for Ct-DNA analysis [14, 18]
BEAMing. The workflow involves multiple steps: The workflow involves
multiple steps:
1)
2)
3)
4)
5)

Coupling biotinylated oligonucleotides to streptavidin beads.
Formation of microemulsions (an aqueous mix of PCR reagents, primer-bound
beads. and DNA template mixed together with an oil/detergent mix).
Conventional PCR.
Breaking the emulsion, purification of the beads using a magnet.
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6) Incubation of the beads with different oligonucleotides.
7) FC to differentiate between different fluorescent beads.[114]
The technique has not been widely applied due to high cost, laborious workflow
and low throughput. [113]
Clinical utility of BEAMING and ddPCR. In Colorectal Cancer patients, CF
Tumor DNA has been used to identify actionable drug targets, track tumor dynamics
throughout therapy as well as, monitor resistance to EGFR-blocking agents. Oncogenic
mutations in RAS, NRAS and BRAF detect the lack of response to EGFR-blockade. By
studying the mutations in the RAS pathway in matched tissue and blood samples, CtDNA showed 97% concordant results. Additionally, it was able to capture mutations not
detected in tissue samples in 8% of the patients, confirming its postulated capability to
capture tumor heterogeneity. In a patient cohort refractory to EGFR, NGS has also
allowed for the identification of somatic mutations in p53 and APC (known to be
commonly mutated in CRC), somatic mutations in MEK gene, in addition to successfully
detecting amplifications in ERBB2 and FLT3.
Ct-DNA successfully detected mutations associated with acquired (secondary)
resistance to anti-EGFR antibodies (panitumumab or cetuximab) in colorectal cancer
patients who progressed on treatment, Ct-DNA analysis was able to detect the presence
of KRAS mutations in 73% of the patients, EGFR ectodomain mutations as well as,
KRAS and MEK amplifications.
Longitudinal analysis of Ct-DNA in 5 the patients with KRAS mutations showed
that the fractional abundance of KRAS mutations emerging at time of relapse, decreases
upon suspension of the first line drug and remain below the level of detection with
subsequent treatment.
Moreover, the study addressed the change in clonal evolution in a limited number
of patients (3 patients) who received multiple rounds of anti-EGFR antibodies. The
change in percentage of KRAS mutated alleles was carried in tissue or plasma samples.
The KRAS clones decline upon suspension of EGFR blockage and increase after rechallenge with anti-EGFR, despite partial response to the second line EGFR, showed the
plasticity of CRC treated with EGFR blockade. This plasticity clearly shows the
implication longitudinal real-time monitoring would have on treatment decisions which
would otherwise depend an outdated molecular profile. It also supports the approach of
adaptive therapy. The authors recommend that each new round of therapy should be
selected based on a recent comprehensive molecular profile of the disease. Hence, the
plasma-based detection of Cf Tumor DNA may provide a more comprehensive
interrogation of the mutational status of the RAS pathway than does the tissue-based
molecular studies. [18]
Hence, Ct-DNA has a potential role in monitoring both intrinsic resistance due to
primary tumor heterogeneity, as well as to dynamically tracking the acquisition of
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secondary resistance to therapy through the selection of additional molecular alterations.
[18]
Massive Parallel Sequencing (MPS) approaches. The study of tumor
heterogeneity and evolution has been limited by the number of genetic lesions studied
and/or the sensitivity of the techniques applied. [10] The advent of MPS, and associated
improvement in sequence quality, read length and throughout have allowed it to provide a
reliable method for Ct-DNA quantification. Although some limitations do exist; namely
the efficiency of capturing the regions of interest and the high error rate of sequencing,
different approaches to overcome associated limitations and decrease the error have been
successfully applied. [89]
Techniques for quantifying Ct-DNA by MPS are classified into two main
approaches, PCR-based on the amplification of the regions of interest using highly
multiplexed specific primers and hybridization capture approaches in which to
oligonucleotide probes complementary to the region of interest are used for capture
followed by library amplification. Finally, deep sequencing is carried out to allow
accurate quantitation of the relative amount of both wild type and mutant DNA at every
specific locus. [89] The detection limit of Ct-DNA by ultrasensitive profiling is
challenged by Cf-DNA recovery and errors introduced during library preparation and
sequencing. [115]
Hybridization-capture based techniques. This approach involves barcoded
library construction, followed by hybridization of the library(s) to oligonucleotide probes
complementary to the region of interest. This is followed by isolation of the captured
molecules (i.e. using streptavidin bead) then amplification using primer sets
complementary to the library barcodes. [89]
Hybrid capture techniques comprise either on-array capture or in-solution capture,
both being based on the use of oligonucleotide probes complementary to the regions of
interest of the barcoded library. The main difference, however, is the amount of DNA
library and oligonucleotide probes. On-array capture use excess amount of library to
oligonucleotide probes, hence requiring a library amount of 10–15μg as an input. [116]
On the contrary, in solution capture utilizes excess probes over the DNA library, allowing
capture from low input DNA library, [117] hence making it capable for use in Ct-DNA
analysis. [89]
The advantage is this approach is the decreased contamination from non-apoptotic
sources, due to lack of shearing step, which increases the Ct-DNA content of the library
leading to an increased percentage of mutant Ct-DNA entering the analysis pipeline as
compared to PCR-based methods. However, the technique is challenged by the low DNA
quantity and quality. [89]
A remarkably successful application of the use of hybridization capture
enrichment strategy for NGS quantification of Ct-DNA is “cancer personalized profiling
by deep sequencing (CAPP-Seq.)”, developed by Newman and colleagues. [115]
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However, it requires a priori knowledge of recurrently mutated genes in the cancer of
interest. [89]
Whole Exome Sequencing (WES). Whole exome sequencing can be utilized
when a priori knowledge about mutations are lacking. [89] In a study of 6 adult patients
with different solid tumors (Breast, Ovarian and Lung), Murtaza et al.2013 used exome
sequencing of cell free tumor DNA to follow the genomic evolution of metastatic cancer.
They were able to demonstrate that Ct-DNA represents the tumor genome. Additionally,
they successfully tracked the change in MAF of the mutations detected in plasma after
different courses of therapy; providing evidence for the utility of WES of Ct-DNA in
monitoring clonal evolution and emergence of therapy resistance.
The small number of patients recruited represents as limitation. Additionally, the
selection of samples with high allele frequency (as detected by ddPCR and taggedamplicon deep sequencing (TAm-Seq.) limits the generalization
of such findings to diseases with low Ct-DNA as well as, cases with low MAF.
Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq.). The main aim
for developing CAPP-Seq. was the design of a method capable of detecting somatic
alterations in the majority of patients without the need of patient specific optimization at
a reasonable cost. Newman and colleagues designed a selector for NSCLC, optimized the
method and tested its clinical applicability in different stages of NSCLC.
CAPP-Seq. selector design. The selector is made up of biotinylated DNA
oligonucleotides complementary to recurrently mutated regions in a specific cancer.
Designing the selector comprises the combination of library preparation techniques from
low input DNA to a 6-phase bioinformatics approach. The initial phase of the selector
design involved the selection of genomic regions carrying known driver mutations in
NSCLC from Catalogue of Somatic Mutations in Cancer (COSMIC). This was followed
by the addition of exons that contain recurrent SNPs detected in 407 NSCLC by WES
from The Cancer Genome Atlas (TCGA). The priority for exons to be included in the
CAPP-Seq. NSCLC selector was done based on 2 metrics; Recurrence index (defined as
“the number of unique patients (i.e., tumors) with somatic mutations per kilobase of a
given genomic unit (i.e. exon) as well as, the number of unique patients (i.e. tumors) with
mutations in a given genomic unit. This allowed for keeping the selector size at
minimum, while maximizing the number of missense mutations per patient. The authors
then added exons of potential driver mutations. Finally, the authors added exons and
introns with breakpoints for ROS1, ALK and RET rearrangements. [115]
The total selector size is 125 kb targeting mutations in 139 genes (521 exon and
13 intron), offering the ability to detect 4 SNPs and to cover 96% of adenocarcinoma and
squamous cell carcinoma patients. [115] The performance of CAPP-Seq. selector for
NSCLC was carried by analyzing samples from cell lines, matched circulating
DNA/leucocytes from NSCLC patients, Cf-DNA from healthy adults as well as, NSLC
patients. The selector capture demonstrated uniformity and efficiency as shown by the
size of the sequenced fragments. [115]
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The technique was optimized through studying different factors that would affect
the limit of detection as well as accuracy of the approach have been studied. The recovery
rate was in accordance with that of PCR, the sample cross contamination was 0.06% in
multiplexed circulating DNA, the allelic bias towards reference alleles was minimum (as
studied by analysis of heterozygous germline SNVs in peripheral blood) whereas the
PCR and sequencing errors as measured by non-reference alleles distribution across the
selector, showed to be reduced as compared to other techniques (mean background rate
0.006% and median background rate 0.0003%). Further steps showed that the biological
background doesn’t highly affect the quantitation of Ct-DNA at limits of detection >
0.01%. Importantly, the detection of fractional abundances at a range of > 0.02%
(0.025% and 10%) were accurate and highly linear. [115]
Clinical utility of CAPP-Seq. CAPP-Seq. demonstrated utility in different aspects
i.e. MRD monitoring, molecular profiling, assessment of response to therapy as well as,
prediction of relapse free survival.
CAPP-Seq. Ct-DNA quantitation pre- and post- treatment accurately detected
MRD in primary Stage I-III lung cancer patients. In the group of patients with Ct-DNA
detected pre-treatment, MRD status (+ve/-ve) post treatment showed significant
correlation with 3-yr progression-free as well as, event-free survival. The Ct-DNA MRD
could actually predict disease progression (positive predictive value 100% and a negative
predictive value 93%).[118]
In DLBCL, CAPP-Seq. showed utility in subtyping and risk stratification. First,
somatic variants in genomic DNA were used to design Cell-of-origin classifier (CCO).
CAPP-Seq. was then used to assess the performance of the classifier in tumor and plasma
samples. CAPP-Seq. results for tumor and plasma were highly concordant (88%-93%).
Initial Ct-DNA levels prior to treatment showed significant correlation with disease
biomarker (LDH) and imaging (PET/CT metabolic tumor volume), International
Prognostic Index (IPI) and, disease stage, hence, allowing for risk stratification of this
group of patients. It was also shown that CCO by CAPP-Seq., in either plasma or tumor,
can significantly predict PFS in this group of patients. [119]
Studies also showed that Ct-DNA analysis by CAPP-Seq. can carry a role in
selecting patients most likely to benefit from therapy, hence guide the clinical decision,
consequently leading to a better outcome. In metastatic NSCLC, Ct-DNA quantitation by
CAPP-Seq. was compared to CT scans (standard of care) for post immune checkpoint
inhibitors (ICI) treatment response. Both Ct-DNA analysis by CAPP-Seq. and CT scans
were done pre-treatment, and repeated post treatment every 6 weeks for CAPP-Seq. and
every 2 months for CT scans. The first response assessment by CAPP-Seq. was done
after a mean of 41 days from commencement of treatment compared to a mean of 60 days
for CT imaging. Patients with partial response or stable disease (durable clinical benefit
(DCB)), showed significant reduction in Ct-DNA as compared to patients with no
durable benefit (NDB). Moreover, 100% of the patients who had undetectable Ct-DNA
were in the DCB group. Hence, Ct-DNA would allow for earlier assessment of response
to therapy and consequently patients who would benefit from ICI. [120]
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CAPP-Seq. utility in defining drug resistance mechanisms. Analysis of Ct-DNA
by CAPP-Seq. proved beneficial in unveiling inter- and intra-patient heterogeneity of
drug resistance mechanisms. Chabon. et al. applied a 302 kb CAPP-Seq. selector
targeting 771 regions in 252 genes, followed by Illumina Hi-seq. 2500 High Output
sequencing (median depth app. 5,500 x) for the analysis of sequential samples from
T790M-positive NSCLC patients. They discovered inter- and intra-patient differences in
the mechanism of resistance to different generations of tyrosine kinase inhibitors (TKIs)
utilized in first as well as, second line treatment. [88]
In agreement with other studies, analysis of Ct-DNA by CAPP-Seq. was
successfully applied for the molecular profiling. Pre-treatment (Pre-Rociletinib treatment,
i.e. at progression on a first or second generation TKI) tumor and plasma samples showed
high level of concordance for EGFR activating mutations and T790M (conferring
sensitivity to Rociletinib). [88]
The authors showed that pre-treatment samples (resistant to first or second
generation TKIs) harbor T790M in addition to other alterations (SNVs and CNV
including MET), at a high frequency. The effect of such alterations (other than T790M)
on response to Rociletinib was further investigated.
The change in clonal dynamics during Rociletinib therapy was also shown.
Analysis of Ct-DNA captured the change in the relative ratio of T790M subclone to the
EGFR activating mutation after the initiation of Rociletinib therapy. The relative ratio of
T790M subclone to the activating mutation, in concordance with the results obtained
from tissue biopsy, significantly declined at progression on Rociletinib therapy,
indicating that Rociletinib is preferentially active against this subclone. Additionally, the
ratio of T790M to the activating mutation before Rociletinib initiation was significantly
correlated with the treatment response; where patients with ratio ≤ 0.5 showing poor
response compared to other patients, thus carrying a potential prognostic value. [88]
The group utilized the detected change in clonal dynamics, as measured by the
change in the fractional abundance of putative resistance mutations, to unravel new
mechanisms of resistance. As was the case with first line TKIs, Ct-DNA analysis
revealed the heterogeneity of resistance mechanisms including MET copy number gain,
concurrent SCNAs and SNVs in 65% of the patients developing resistance to Rociletinib.
Based on the hypothesis that mutations driving resistance would be positively selected
with therapy; an increase in the fractional abundance of the subclone harboring METcopy-number-gain led to further investigation of patients harboring the alteration. The
authors were successfully able to demonstrate that MET-copy-number-gain confers
resistance to Rociletinib, and that patients harboring MET-copy-number-gain experience
a worse outcome. Interestingly, they were able to show that combination of Rociletinib
and Crizotinib (MET inhibitor) leads to restoration of Rociletinib sensitivity in RR cells
and patient-derived NSCLC xenograft model. [88]
More importantly, the study demonstrated a significant correlation between
different mechanisms of resistance and PFS. Antecedent copy number gain in MET,
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EGFR and ERBB2 was associated with PFS < 3 months (described by the authors as
innate resistance), whereas a (PFS > 3 month) was associated with SNVs (described as
acquired resistance). Another seminal finding was the discovery of novel EGFR (L798I)
tertiary mutation a KRAS activating mutation after TKI treatment in EGFR mutated
NSCLC. [88]
Taken together, the aforementioned findings clearly demonstrate the therapeutic
implication of Ct-DNA analysis in guiding therapy. In cases where multiple resistance
mutations/mechanisms co-exist, single-pathway inhibition might be insufficient to elicit
the desired response.[88] Ct-DNA holds a great promise in identifying patients who are
more likely to benefit from single drug versus those who require a combination regimen.
It follows that, incorporation of Ct-DNA analysis at diagnosis and throughout therapy,
would not only impact the outcome; but also, the cost associated with administration of
non-effective therapy. [88]
Error Suppression for Deep Sequencing
For all applied sequencing approaches, a PCR step is included for Cf-DNA
libraries enrichment. Despite using high-fidelity polymerases, which combine
proofreading activity (3´→5´ exonuclease activity) with low error rates and keeping PCR
cycles at minimal; the errors generated from PCR and sequencing (i.e. errors existing
with bridge amplification at illumina platform) [121] remain a challenge for accurate
detection of low frequency alleles. [89, 115] Accordingly, the goal of error suppression
methods is to be able to discriminate between reads originating from an original duplex
and those originating from other fragments covering the same locus (i.e. representing
different alleles or cells).[89]
Molecular indices comprise either random nucleotides, partially degenerate or
defined nucleotides (in case of low template input) have been successfully employed to
tag. [122]; single DNA strands or double-stranded DNA molecules. Single-strand
molecular barcoding is associated with higher efficiency; whereas duplex molecular
barcoding better suppresses errors.[123] Two error suppression methods are introduced
here, Safe-SeqS and iDES.
Safe-Sequencing System (“Safe-SeqS”). This approach mainly utilizes tagging
of individual templates using endogenous or exogenous unique identifier (UID) and
nested PCR amplification to amplify each uniquely tagged DNA molecules; for each UID
tagged molecule, amplification results in UID family; each strand of the original duplex,
produces a uniquely identified fragment. Accordingly, a true mutation that exist in the
original template should be present every daughter molecule i.e. shared across the UID
family. This is followed by redundant sequencing; UID reads are used to organize the
reads into a “UID family”. UID is designed as “supermutant” if the mutation is shared in
95% of the family members. [121]
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The introduction of an endogenous UID is employed through introducing an
exogenous sequence by PCR, ligation to the end of the DNA template; or shearing (in
case of genomic DNA) and using original template ends as tags. The detailed method
introduced by Kindle and colleagues utilizes shearing, which can’t be employed in the
case of Ct-DNA as the fragment end distribution is not random. Briefly, shearing is
followed library preparation, solid-surface capture, amplification and sequencing. Upon
determination of the error rate with and without Safe-SeqS, the authors concluded that
Safe-SeqS was associated with a 9-fold decrease in the error rate. [121]
Exogenous UID strategy for Safe-SeqS involves amplification with a set of
primers targeting the gene of interest. The UID (random sequence 12-14 N) is attached to
one of the primers at its 5’ end; both primers have universal sequence for later PCR
amplification. Two PCR cycles are carried out to assign UID; as in the case of
endogenous UID, each duplex produces two uniquely identified fragments. This is
followed by PCR, using universal primers; followed by sequencing where the generated
reads are used for UID family assignment and supermutants detection. [121]
Advantages of Safe-SeqS exogenous strategy is that it allows not only for the
detection of the fraction of templates harboring the variants; but also, the quantitation of
the number of templates analyzed. The technique can analyze low input samples with
minimal template loss. Comparing Safe-SeqS to conventional analysis of illumina
sequencing data showed an error reduction of 24- and 15-fold respectively when
analyzing the prevalence of rare mutations in a single gene from human cells or short
mitochondrial gene segment respectively. [121]
The applicability of the technique in analyzing multiple amplicons from a lowinput sample has not been studied; multiplexing is proposed to combat such a drawback.
Additionally, Safe-SeqS success is dependent on the efficiency of early amplification
cycles for UID assignment, which can be affected by the presence of inhibitors in the
clinical sample. Also, during library enrichment, polymerase error can generate a new
UID family; consequently, creating an artificial supermutant. Additional criteria for the
analysis would help mitigate the effect of such factor. [121]
Integrated Digital Error Suppression method (iDES). Low concentration of
Ct-DNA, especially post-treatment, represents a challenge for ultrasensitive detection
techniques. CAPP-Seq. had > 50% sequencing artifacts below an allele frequency of
0.02%. Newman et al. 2016 developed iDES error suppression method to overcome the
sequencing errors challenging CAPP-Seq. at detection limit below 0.02%. [123]
Newman and colleagues designed “Index adapters” and “Tandem adapters”;
detailed as follows.: (1) “Index Adapters” comprise a re-design of the original 8-base
multiplexing barcode; an 4-mer “index barcode” is incorporated into the single stranded
part of the adapter, adjacent to the now 4-base multiplexing barcode. During sequencing,
Index barcodes are read with index reads. (2) “Tandem Adapters” include two exogenous
index reads (to uniquely barcode each single strand of the original duplex) and two 2base-double stranded-UID “insert barcodes” integrated into the ds part, adjacent to the
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ligating side, of the adapter. Insert barcodes are sequenced as part of the main read (at the
beginning and the end of the read). Hence, for paired-end sequencing, 4-base UID is
assigned to every single DNA strand. The authors note that that the position of insert
and/or index barcode, as well as the length can be altered in different adapter designs to
achieve the desired level of molecular diversity. [123]
The effect of “Index” and “Insert” barcodes on error suppression was evaluated
using the NSCLC CAPP-Seq. selector previously described (under CAPP-Seq. Selector
Design). Analysis done incorporating “index barcode” only resulted in 2.5-fold
improvement in the mean error rate detected in the CAPP-Seq. approach; whereas the
incorporation of “insert” barcode only exceeded “index barcode” by 1.25 -fold.
Employing both barcodes, the overall error rate was 9x10-5 error/base. [123]
Cell-free sequencing data showed that G>T transversions represent the majority
of background errors. In their analysis for possible causes; Newman and colleagues were
able to exclude in vivo oxidative damage and strand bias in sequencing as causes for such
increase in G>T transversions. Evaluating different times associated with hybrid capture,
they demonstrated that most of the errors is generated post ligation and during the
enrichment step of strand-specific target sequence. To mitigate background error, the
authors designed a computational method “Background Polishing” through employing
position-specific error modeling in a control cohort to allow error suppression in
independent samples. [123]
Combining barcoding with background polishing “iDES” resulted in a 15-fold
reduction of overall error rate (1.5 × 10−5 errors per base) achieving 98% error-free
positions (as compared to 90%). [123]
The effect of iDES on the recovery rate (a known important factor affecting the
detection limit) was evaluated using 32 ng of Cf-DNA. Post-capture recovery rates of
60% were achieved for ∼ 10,000 input hGE, hence reducing errors without negatively
affecting the efficiency of recovery. [123]
Furthermore, the effect of iDES on CAPP-Seq. detection limit was validated. A
Glioblastoma multiforme personalized CAPP-Seq. selector was designed to cover 1502
non-synonyms SNV; 32 ng of healthy Cf-DNA were spiked various proportions of GBM
DNA molecules. The iDES-enhanced-CAPP-Seq. limited of detection was 10-fold below
that reported for CAPP-Seq. i.e. 0.0025% (using 30 mutations and ∼ 3000 hGE). [123]
In samples obtained from NSCLC patients prior to clinical progression, a
detection limit of 0.004% was achieved. iDES-enhanced-CAPP-Seq. successfully
detected Ct-DNA in 93% of patient prior to treatment; and significantly detected in 73%
of pre-and post-treatment samples (Specificity 100%). [123]
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Ct-DNA in Hematological Malignancies
Employing advanced molecular approaches, proof-of-concept studies have
demonstrated the utility of Ct-DNA analysis for mutational profiling and longitudinal
monitoring in different hematological malignancies. [14, 17]
In patients with Myelodysplastic Syndrome (MDS), targeted deep sequencing of
55 genes (known to be mutated in MDS) detected the driver mutations with 100%
concordance between matched BM and plasma samples. Moreover, the MAF detected in
Ct-DNA showed an excellent correlation (r2 = 0.84) with that measured in BM across
most of the matched points, providing evidence for Ct-DNA as a non-invasive biomarker
for disease monitoring. Importantly, monitoring of somatic mutations and karyotype
abnormalities throughout therapy; successfully predicted treatment failure. [17]
The utility of somatic mutation detection in Ct-DNA in monitoring disease
progression was also demonstrated in Multiple Myeloma (MM), where the change in the
fractional abundance of a clone specific mutation showed concordance with the clinical
disease status i.e. increase in FA coincided with disease relapse or moreover, occurred
prior to serological markers detection. [14]
Furthermore, Ct-DNA analysis showed applicability in the comprehensive
characterization of MM mutational landscape, as an adjunct to BM. Mithraprabhu et al.
utilized OnTarget mutation detection platform which includes 96 mutations in the KRAS,
NRAS, CTNNB1, EGFR, PIK3CA, TP53, FOXL2, GNAS and BRAF genes, to study
BM and plasma of newly diagnosed and relapsed/refractory MM patients. Out of total
128 mutations detected, 46% showed concordance between BM and plasma, 30% were
detected in BM only, whereas 24% were detected only in plasma; hence giving a
supporting evidence for the presence of spatial heterogeneity in MM. [14]
Ct-DNA in Pediatric Leukemia
Studies of Cf-DNA in pediatric leukemia focused on the quantification of
leukemia MRD, done by RQ PCR using allele specific oligonucleotide (ASO) primers for
Ig/TCR targeting the junctional region, during early phase of treatment.[124, 125] In
accordance with previous studies showing a higher Cf-DNA concentration in cancer
patients, higher total plasma DNA was detected at diagnosis in pediatric ALL, as
compared to healthy children, which decreased back to normal levels by D4. Sequential
quantification of total plasma DNA, and leukemic MRD in pediatric ALL patients at
specific time points during induction phase, demonstrated significantly higher plasma
total DNA level initially and at D3 versus later time points, which correlated to the
leucocyte count. Slight elevation in total DNA concentration was detected on D33 and
week 12, alongside with marrow regeneration. Leukemia MRD detected qualitatively
showed high concordance (86%) with MRD detection in leukocytes. [124] Leukemia
MRD was below the limit of detection (cutoff of 10-5) at D33 and week 12. Despite the
lack of correlation between FC-MRD and plasma leukemic MRD, plasma leukemic MRD
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(D15, cutoff of 10-4) showed an independent correlation to the risk of relapse in both
univariate and multivariate analysis in Chinese children. [125]
Limited by the sensitivity of the techniques used [126], the studies couldn’t
solidify a role for Ct MRD quantification of Ct-DNA, yet, they clearly demonstrated the
feasibility of analyzing Ct-DNA in this group of patients, showing that the analysis of CtDNA in pediatric leukemia carries great promise if more advanced sensitive techniques
are incorporated in the analysis.
Rationale of the Study
Multiple genetic factors play a role in the pathogenesis and prognosis of pediatric
leukemia. Interaction occurs between inherited and somatic genetic alterations, where
specific inherited alleles predispose to specific chromosomal-defined subtypes. [1] The
genetic landscape of leukemia is further complicated by the genetic heterogeneity; the
disease reported to be polyclonal in 50% of the patients at diagnosis. [2] Additionally,
pharmacogenomic determinants of drug response and toxicity affects the outcome [3].
MRD-adapted therapy, in which risk stratification is based on biological features
and response to therapy has been associated with an improvement in the treatment
outcome. [4] Nevertheless, within the favorable risk group, a substantial number of
patients, relapse. [5]
Advancement in the molecular techniques have provided a deeper insight into the
biology of relapse. In most cases, relapse emerged from a minor clone at diagnosis or
rather a pre-ancestral clone which survived therapy, acquired additional mutations to
become the relapse founder clone. Moreover, mutations enriched at relapse were
unraveled as well as, in many cases their association with drug resistance. [9, 11, 57]
Although several studies have addressed the role of clonal evolution in relapse [3,
7], the change in clonal dynamics has been only studied at diagnosis, remission and
relapse. Hence, the knowledge of real-time change in the clonal dynamics, in response to
therapy, remains obscure.
Also, despite the demonstrated impact of heterogeneity on clonal evolution and
relapse, comprehensive characterization of the disease at diagnosis or throughout therapy
is still limited. This is attributed to the inherent limitations in the currently applied
strategies for ALL diagnosis and follow up. Two main limitations hinder the detection of
clonal diversity at diagnosis and longitudinal follow up of clonal evolution. Firstly,
samples for response assessment are obtained through single-site BM biopsy. The
invasiveness of the technique hinders its use for sequential analysis. [6,7] Additionally, a
single BM aliquot fails to capture
tumor heterogeneity associated with spatially
separated subclones. Secondly, MRD assessment is done either by Flowcytometry or
PCR, both of which lack the ability to detect subclones that differ from the major
diagnostic clone. [8,9]
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The finding that an increase in the percentage of mutations conferring resistance
precedes clinical relapse, together with the successful reversal of resistance using small
molecules or targeted therapies, implies the importance of incorporating techniques
capable of tracking clonal dynamics into clinical management protocols. [10]
Hence, the development of biomarker that is capable of real-time follow up of
clonal dynamics and therapy resistance carries great promise in leukemia monitoring,
consequently guiding therapy.
Ct-DNA was shown to be derived from different malignant subclones and hence
offers a representation of tumor heterogeneity and would thus provide a better
characterization of disease behavior than does currently used quantitative methods based
on the detection of the most dominant diagnostic clone. Importantly, it would serve as a
minimally invasive technique, which can be repeated at multiple time points. [11]
Several proof-of-concept studies have demonstrated the utility of Ct-DNA in
different application in various hematological and solid cancers. [11,12,13,14]. The
analysis of Ct-DNA showed high degree of concordance to BM or tissue biopsy;
demonstrating its utility in molecular profiling. [11,12]. Additionally, measurement of
MAF in Ct-DNA showed utility in longitudinal monitoring of the disease [14]. Moreover,
analysis of Ct-DNA allowed for tracking drug resistance and discovering drug resistance
mechanisms. [11,13]
However, studies of Ct-DNA in pediatric leukemia were limited by the sensitivity
of the techniques used yet, they were still able to demonstrate its feasibility in sequential
analysis during early treatment phase of treatment. [15,16]
Study Objective
In this project, we study the utility of somatic mutation detection in plasma CtDNA as a method for molecular profiling at diagnosis, as well as monitoring tumor
dynamics throughout therapy. We employed WES for the first recruited patients;
however, data analysis was challenged by the large number of mutations detected and the
difficulty to discriminate true mutations from false positives. For the next group of
patients, we applied targeted sequencing using ALL customized gene panel. The MAF is
compared across different time points as well as, between BM and Plasma samples at
matched time points.
Our long-term goal is to incorporate Ct-DNA in the clinical protocols as a
minimally invasive biomarker for comprehensive molecular profiling and longitudinal
monitoring of the disease in pediatric ALL
NGS was applied to study somatic mutations in peripheral blood (PB)/bone
marrow (BM) plasma Ct-DNA at diagnosis, at specified time points during, and at the
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end of remission induction therapy. MAF was calculated for all the specified time points.
The specific aims of the current work are:
1) Testing the utility of Ct-DNA in capturing ALL tumor heterogeneity at diagnosis.
MAF detected by Ct-DNA analysis of diagnostic PB plasma is compared to MAF
detected by clinical WES of diagnostic BM biopsy sample.
2) Testing the utility of Ct-DNA in monitoring the change in clonal dynamics during
remission induction therapy. Somatic mutation detection in Ct-DNA was
compared to FC based clinical MRD, with a specific focus on patients with
negative MRD.
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CHAPTER 3. METHODOLOGY
Patients and Samples
All patients were enrolled in Total Therapy Study XVII (TOTXVII), St. Jude
Children’s Research Hospital. Samples were collected with informed consent for research
use and approval of IRB. BM samples were collected at time of diagnosis, D15 and at the
end of induction. Peripheral blood samples were collected at diagnosis, Induction therapy
D3, 8, 15, 22 and at the end of induction.
Separation of Plasma from Peripheral Blood
Blood samples were collected, at the specified time points during induction
therapy, in K2EDTA tubes and plasma separated as follows: samples were diluted with
PBS in a ratio 1:1, followed by centrifugation at 1600 g (10 min) , plasma is then
separated and re-centrifuged at 14000 rpm (10 min.) to remove any residual cells, then
stored at -80°C as 1 ml aliquots until Cf-DNA extraction. BM and blood samples were
fractionated by the biorepository staff.
Cell-free DNA Extraction and Quantification
Cf-DNA was extracted from 650 μl – 1000 μl (average 950 μl) of plasma or noncellular BM (BM plasma) using Maxwell RSC ccfDNA Plasma Kit, according to the
manufacturer’s protocol using 40 μl Qiagen elution buffer. Following extraction, CfDNA was quantified using Qubit dsDNA High Sensitivity Kit.
Technical details for using Maxwell RSC ccfDNA Plasma Kit can be accessed at
https://www.promega.com/resources/protocols/technical-manuals/101/maxwell-rscccfdna-plasma-kit-protocol/. [127]
Construction of Adapter-ligated Libraries
For each sample, the whole amount of Cf-DNA isolated was input into library
preparation. Library preparation was carried out by NEBNext® Ultra™ II DNA Library
Prep Kit for Illumina (NEB #E7645) according to manufacturer’s protocol with few
modifications: (1) no size selection was done irrespective of the input (2) Kappa 10x
primer mix was used for PCR enrichment of the adapter-ligated libraries (3) For WES,
dual indexed adapters were used whereas for targeted capture, index barcoded adapters
were employed (4) Qiagen EB buffer was used for elution.
Since no pooling guidelines were available for Nextseq, we selected adapter
combinations based on TruSeq DNA Sample Preparation Guide (Pooling Guidelines) for
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Hiseq./Miseq. (https://support.illumina.com/content/dam/illuminasupport/documents/documentation/chemistry_documentation/samplepreps_truseq/truseqd
na/TruSeq_DNA_SamplePrep_Guide_15026486_C.pdf) [128] as well as, general pooling
guidelines (https://support.illumina.com/bulletins/2016/10/library-pooling-guidelines-forthe-nextseq-and-miniseq-systems.html). [129]
Post PCR clean-up was carried as single or double-sided cleanup. Libraries were
quantified using Qubit ds-DNA High Sensitivity Kit. Following library preparation and
quantification, QC Miseq run was performed for assessment of the quality of the
sequencing libraries prior to hybridization capture.
Hybridization-based Capture and Sequencing
For each case, libraries (equivalent to pre-defined induction time points) are
pooled (multiplexed) together (in a ratio 1:1) into one capture.
For WES, hybridization-based exome capture was done according to IDT
protocol Hybridization capture of DNA libraries using xGen® Lockdown® Probes for
Illumina HT- Adaptor Ligated Libraries according to manufacturer’s protocol, using
xGen® Exome Research Panel which consists of 429,826 probes, spans a 39 Mb target
region (19,396 genes) of the human genome and covers 51 Mb of end-to-end tiled probe
space. Enriched libraries were quantified using Qubit™ dsDNA BR Assay Kit. QC
Miseq run was performed for assessment of the quality of the pooled libraries prior to full
Nextseq run employing Illumina Nextseq High Output lane.
For targeted capture, the same protocol was applied using the custom gene panel
which covering ≅ 1668 exons and 319.4 kb.
Design of the Mutation Capture Panel
A specific ALL custom gene panel was designed by our lab. computational
biologist. Initially, the list combined a number of genes known to harbor somatic
mutations in ALL derived from different pathways/sources (1) Oncogenic pathway,
(2) Tumor suppressor genes, (3) Relapse-specific genes, (4) Drug metabolism, (5)
CRISPR/Cas9 screening (unpublished data), (6) Genes associated with glucocorticoid
resistance, (7) xGen® Pan-Cancer Panel (which includes list of genes derived from
TCGA; known to be mutated across multiple cancer types. Finally, the genes which
harbored ≥ 3 non-synonyms SNVs in B-cell or T-cell (either at diagnosis or relapse) in
the SiTH database (derived from ≅ 500 patients) were selected for the final panel. Probes
were designed to the genomic regions surrounding the mutations (Personal
communication with Ousman Mahmoud on 17th March 2018, Charles Gawad Lab. St.
Jude Children’s Research Hospital) (Appendix A. List of Genes of Custom ALL
Panel).
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Processing of Sequencing Data
For WES, Trimmomatic was employed for trimming adapters and illumina
sequences. Sequence reads were aligned to the reference genome using Burrows-Wheeler
Aligner (BWA-aln/sampe). Alignments were sorted by co-ordinate using Picard.SortSam.
GATK was employed for marking duplicates, local realignment and base-recalibration.
Variant calling and filtering was performed using Mutec2. Annotation was carried out
using Annovar.
For targeted sequencing using the ALL customized gene panel, sequence reads
were de-multiplexed using Picard, FgBio, Samtools. Sequence reads were aligned to the
reference genome using Burrows-Wheeler Aligner (BWA-aln/sampe). Fgbio was
employed for UMI consensus calling. Reads were grouped by UMIs (Fgbio –
GroupReadsByUmi) Consensus reads generated (Fgbio –CallMolecularConsensusReads)
and filtered (Fgbio– FilterConsensusReads). Sequence reads were aligned to the
reference genome using Burrows-Wheeler Aligner (BWA-aln/sampe). GATK was
employed for marking duplicates, local realignment and base-recalibration. Varscan was
applied for mutation detection. Variant filtering was done according to specific criteria
including: the presence in ≥ two time-points, location within the target region, Nonsynonyms mutation and absence from germline. Additionally, mutations detected in
sequence repeats are removed as well as, those present across multiple samples.
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CHAPTER 4. RESULTS
Study Design and Patient Enrollment
14 patients recruited in St. Jude Total Therapy Study XVII were included in the
study. B-cell precursor comprised 11/14 (78.6%) whereas T-cell represented 3/14
(21.4%). The patients’ age ranged from 2.6 to 17.3 years (Table 4-1). Using NCI risk
criteria for classification of precursor B-cell cases, 4 patients were classified as High risk
(WBCs ≥ 50,000 cells and/or Age ≥ 10 years) and 7 patients were Standard risk (WBCs <
50,000 cells and/or Age < 10 years). Provisional risk stratification as well as, final risk
stratification according to Total XVII study is summarized in (Table 4-2). Total XVII
provisionally classifies patients into three risk groups (low-, standard-, or high risk)
according to several presenting features (age, TLC, CNS status, molecular, cytogenetic
diagnosis and immunophenotyping (IPT). Early response to therapy, as measured by
MRD during and at the end-of-induction therapy dictates the final risk stratification.
(Appendix B. Total XVII Risk Stratification).
In Total study XVII, NGS is implemented as a diagnostic clinical standard-of-care
for all patients enrolled in the protocol. WGS, WES and transcriptome sequencing are
carried by the clinical pathology lab.; genetic alterations with relevance to diagnosis or
management are reported in patients’ clinical records. Total XVII therapy implies
Flowcytometry based MRD for response assessment during induction therapy and
throughout treatment. During induction, MRD is evaluated in BM on D15, D22 (in
patients with D15 MRD ≥ 1%) and at end of induction (D42); whereas MRD evaluation
in PB is carried out on D8.
We performed Ct-DNA analysis in sequential plasma samples withdrawn at
equivalent time points. BM-plasma was evaluated on D1, D15 and at end of induction;
whereas PB-plasma was evaluated on D1, D3, D15, D22 and at end of induction.
Somatic Mutation Detection in Leukemia-derived Cell-free DNA
Cf-DNA was isolated from PB plasma and BM plasma using Maxwell® RSC
ccfDNA Plasma Kit. Extracted DNA was quantified by Qubit™ dsDNA HS Assay Kit.
whole amount of Cf-DNA isolated/sample was used as input into library construction.
Molecular barcoding was incorporated into library preparation for targeted sequencing.
Libraries were quantified using Qubit™ dsDNA HS Assay Kit, analyzed on agarose gel
to confirm the size of the fragments. This was followed by QC Miseq. run for libraries.
Following library construction, samples were either exome captured using IDT Exome
Panel or targeted capture. Post exome or target enrichment, libraries were sequenced on
Illumina NextSeq. 550-platform. Analysis of sequencing data was done by a
bioinformatics pipeline for the detection of somatic SNV.
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Table 4-1.

Patient Characteristics

Case#

IPT

CRLF-2
Expression

Age
(yrs)

Initial
WBCs
(x10e9/L)

Case 1

B-cell

Negative

2.9

4.4

Case 2

B-cell

Positive

3.1

Case 3

B-cell

Negative

Case 4

T-cell

Case 5

CNS
Status

Stemline
DNA
Index

t(9;22)
CML

t(9;22)
ALL

t(1;19)

t(4;11)

t(12;21)

Negative

1.25

Negative

Negative

Negative

Negative

Negative

50.6

Negative

1.05

Negative

Negative

Negative

Negative

Negative

11.1

1

Negative

1.20

Negative

Negative

Negative

Negative

Negative

-----

12.8

189.5

Positive

1

-----

-----

-----

-----

-----

B-cell

Negative

12.3

6.4

Negative

1.18

Negative

Negative

Negative

Negative

Negative

Case 6

B-cell

Negative

2.6

25.7

Negative

1

Negative

Negative

Negative

Negative

Positive

Case 7

B-cell

Positive

17.3

49.7

Positive

1

Negative

Negative

Negative

Negative

Negative

Case 8

B-cell

Negative

3.6

2.5

Negative

1

Negative

Negative

Negative

Negative

Positive

Case 9

B-cell

Negative

7.6

1

Positive

1.24

Negative

Negative

Negative

Negative

Negative

Case 10

ETP

-----

4.8

0.2

Negative

1

-----

-----

-----

-----

-----

Case 11

B-cell

Positive

3.3

5.3

positive

1

ND

ND

Negative

ND

Negative

Case 12

B-cell

Negative

9.3

25.7

Negative

1

ND

ND

Negative

ND

Negative

Case 13

B-cell

Negative

7.7

3.5

positive

1.16

ND

ND

Negative

ND

Negative

Case 14

T-cell

-----

11.3

32.5

Negative

----

-----

-----

-----

-----

-----
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Table 4-2.
Case#

Case 1
Case 2
Case 3
Case 4
Case 5
Case 6
Case 7
Case 8
Case 9
Case 10
Case 11
Case 12
Case 13
Case 14

Classification of Patients into Risk Groups by NCI Criteria and Total XVII Criteria
NCI
Risk

Total XVII
Provisional
Risk

D8 PB
MRD (%)

D15 BM
MRD (%)

Standard
High
High
---High
Standard
High
Standard
Standard
---Standard
Standard
Standard
----

Low
Standard
Low
Standard
Low
Low
Standard
Low
Standard
Standard
Standard
Low
Standard
Standard

0.408
0.071
0.013
<0.01
7.930
0.003
0.738
0.030
0.045
4.370
0.018
16.030
<0.01
38.65

6.820
0.01
2.150
<0.01
0.983
0.016
1.502
0.022
0.191
---0.014
9.936
<0.01
55.203

D15 PB
D22 BM
D22 PB
MRD (%) MRD (%) MRD (%)

---------------------------<0.01
---------47.04
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2.12
----<0.01
---------0.421
------0.958
---2.059
---31.665

---------------------------1.609
---------30.246

EOI BM
EOI PB
MRD (%) MRD (%)

<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
2.981
<0.01
<0.01
<0.01
0.139

---------------------------4.73
---------0.043

Total XVII
Final Risk

Standard
Standard
Standard
Standard
Low
Low
Standard
Low
Standard
High
Standard
Standard
Standard
High

Cf-DNA Isolation and Library Preparation
Samples for WES. An average of 952 μl (800μl-1100μl) plasma/sample was
used as an input to Maxwell® RSC ccfDNA Plasma Kit followed by quantification by
Qubit™ dsDNA HS Assay Kit. The mean concentration of Cf-DNA isolated/sample was
1.35 ng/μl; median= 0.27 ng/μl; range 0.05-34.2 ng/μl); For diagnostic samples, mean=
1.5 ng/μl; median 0.332 ng/μl). The total yield of Cf-DNA isolated/sample was used as
input into library preparation (mean Cf-DNA input to library preparation = 41.5 ng;
median=9.6 ng; range=1.6-950 ng).
Samples for targeted capture. For peripheral blood plasma and BM plasma
samples analyzed, the mean yield of Cf-DNA extracted was 56.6 ng, median=9 ng.
The yield of extraction for peripheral blood plasma samples was 54.5 ng, median =
8.93ng whereas, for BM plasma samples; the mean yield of Cf-DNA extracted was 58.3
ng and the median 9.46 ng.
Gel electrophoresis for Cf-DNA libraries. The fragment size was ∼ 300 bp as
expected for Cf-DNA. Of notice that in some cases bi-nucleosomal inserts yield libraries
of size ∼ 450 bp; ∼334 bp of the bi-nucleosomal Cf-DNA insert + 120 bp (2 *60-bp
Adapter) (Figure 4-1).
Exome Capture
Gel electrophoresis repeated after exome capture confirmed the 300 bp size was
confirmed for the captured fragments (Figure 4-2).
Sequencing Metrics
Post exome capture, Miseq QC run was carried followed by NextSeq. complete
run. QC metrics are described below:
NextSeq. QC metrics for WES. QC metrics for the NextSeq. runs (Table 4-3)
are summarized as follows: average number of reads =110717316.7, average % reads
lligned = 99.39454545, average % read duplicates= 33.39136364 and average %
selected bases (xgen Exome) = 87.79.
Miseq. QC metrics for targeted capture. Miseq QC metrics for the targeted
capture (Table 4-4) are summarized as follows: average % of aligned reads=88.7%
whereas the average % of selected bases=93.94%.
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Figure 4-1. Gel Electrophoresis for Cf-DNA Adapter-ligated Libraries
Case#8 (left) and Case#10 (right)

Figure 4-2.

Gel Electrophoresis for Exome-captured Pooled Libraries (Case#2)
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Table 4-3.

NextSeq. QC Metrics for WES-captured Libraries

Case #

Sample Name
Case01_D01_BMPL
Case01_D01_PBPL
Case01_D03_PBPL
Case01_D08_PBPL
Case01_D15_PBPL
Case01_D15_BMPL
Case01_D22_PBPL
Case01_D42_PBPL
Case01_D42_BMPL

Number of
Reads
155653732
84983694
117168598
8008298
107283528
153753698
106452792
111422134
95648770

% Reads
Aligned
99.56
97.53
99.45
99.29
99.44
99.53
99.43
99.50
99.42

% Read
Duplicates
73.42
14.98
64.00
3.53
53.65
48.28
13.91
32.16
44.80

%Selected Bases
(xgen Exome)
88.97
92.24
89.62
92.04
90.42
91.13
91.96
91.68
90.94

Case 01

Case 02

Case02_D01_BMPL
Case02_D01_PBPL
Case02_D03_PBPL
Case02_D08_PBPL
Case02_D14_PBPL
Case02_D15_BMPL
Case02_D22_PBPL
Case02_END_PBPL
Case02_END_BMPL

166646680
143217210
131912546
144250060
90042306
79915688
88835376
112411712
65827244

99.71
99.71
99.66
99.21
99.75
99.40
99.74
99.73
99.22

14.00
12.83
14.60
20.82
40.96
30.39
83.13
67.40
32.92

92.63
92.55
91.89
82.97
91.16
90.87
84.53
90.90
88.91

Case 03

Case03_D01_BMPL
Case03_D01_PBPL
Case03_D03_PBPL
Case03_D08_PBPL
Case03_D15_BMPL
Case03_D15_PBPL
Case03_D22_PBPL
Case03_END_BMPL
Case03_END_PBPL

122430274
110666618
93000222
101185822
143407628
81486274
76349870
116908314
124942240

99.22
99.33
99.22
99.31
99.35
99.31
99.33
99.35
98.51

19.81
21.45
22.08
35.93
78.32
22.66
22.60
39.51
19.64

82.94
84.53
83.61
82.44
65.89
82.97
83.27
81.72
84.54

Case 05

Case05_D01_PBPL
Case05_D03_PBPL
Case05_D08_PBPL
Case05_D15_BMPL
Case05_D15_PBPL
Case05_D22_PBPL
Case05_END_BMPL
Case05_END_PBPL

164377728
135878598
151060668
124653950
119711104
180899414
100656310
136924480

99.64
99.56
99.57
99.32
99.56
99.63
99.18
99.58

14.76
13.39
14.01
12.06
13.42
70.73
11.58
49.21

88.98
88.24
89.02
88.25
88.16
79.90
88.70
84.22
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Table 4-3.

(Continued)

Case #

Sample Name

Case 06

Case06_D01_BMPL
Case06_D01_PBPL
Case06_D03_PBPL
Case06_D08_PBPL
Case06_D15_BMPL
Case06_D15_PBPL
Case06_D22_PBPL
Case06_END_BMPL
Case06_END_PBPL

Number of
Reads
131321820
137796606
49788616
1761754
119909784
16765330
153520806
92246978
120476660

% Reads
Aligned
99.62
99.62
99.60
99.53
99.25
99.38
99.63
99.81
99.67
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% Read
Duplicates
31.37
12.82
8.61
17.28
54.59
82.45
84.49
11.73
18.94

%Selected Bases
(xgen Exome)
91.28
91.90
92.09
92.21
89.78
85.21
84.51
91.29
91.70

Table 4-4.

Post-capture Miseq. QC Metrics for Targeted-captured Libraries

Case #
Case 01

Sample
D1_PB
D15_PB
D22_PB
D42_PB

% Reads Aligned
77.20
78.58
77.80
79.19

Case 02

D1_BM
D1_PB
D3_PB
D8_PB
D14_PB
D15_BM
D22_PB
D42_BM
D42_PB

77.82
76.95
77.05
76.73
76.10
70.77
76.44
76.19
76.07

93.49
93.99
93.68
93.51
94.01
93.55
92.12
93.91
93.78

Case 03

D1_BM
D1_PB
D3_PB
D8_PB
D15_BM
D15_PB
D22_PB
D42_PB
D42_BM

77.13
77.45
76.89
73.50
75.61
76.88
76.60
82.18
68.10

93.91
94.09
94.55
94.16
93.44
93.39
93.86
94.25
94.03

Case 04

D1_PB
D3_PB
D8_PB
D15_BM
D15_PB
D22_PB
D42_BM
D42_PB

73.73
74.60
84.27
83.81
84.97
85.94
83.20
85.03

94.01
94.43
90.74
91.05
90.80
91.05
91.40
90.97
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%Selected Bases
93.70
93.90
93.15
93.79

Table 4-4.

(Continued)

Case #
Case 05

Sample
D1_PB
D3_PB
D8_PB
D15.BM
D15_PB
D22_PB
D42_BM
D42_PB

Case 06

D1_BM
D1_PB
D3_PB
D8_PB
D15_PB
D15_BM
D22_PB
D42_BM
D42_PB

84.38
84.63
84.30
84.09
85.67
84.19
85.09
81.84
84.81

90.07
89.80
89.1
90.38
89.85
90.22
90.27
89.93
90.56

Case 07

D1_PB
D3_PB
D8_PB
D15_BM
D15_PB
D22_PB
D42_BM
D42_PB
D73_PB

83.81
94.29
93.70
94.27
94.16
94.19
94.28
94.18
92.42

88.12
93.90
94.88
93.64
94.75
95.94
95.03
94.49
94.94

Case 08

D1_PB
D3_PB
D8_PB
D15_BM
D15_PB
D22_PB
D49_PB
D52_BM
D52_PB

94.46
94.21
93.25
94.55
94.29
94.84
93.99
95.65
94.49

96.35
97.43
95.48
96.06
96.65
96.02
96.10
93.72
96.12

% Reads Aligned
85.89
85.26
85.00
85.56
86.07
85.50
80.09
83.92
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%Selected Bases
91.56
91.50
91.56
91.65
90.90
91.46
90.15
89.33

Table 4-4.

(Continued)

Case #
Case 09

Sample
D1_BM
D8_PB
D22_PB
D50_BM
D50_PB

Case 10

D15_PB
D22_PB
D22_BM
D43_PB
D59_PB

94.92
94.40
97.27
97.32
96.98

95.49
90.84
94.33
95.13
94.42

Case 11

D1_PB
D3_PB
D8_PB
D14_PB
D15_BM
D22_PB
D42_BM
D42_PB
D98_PB

97.44
97.48
97.32
96.80
96.67
96.74
96.99
97.29
97.02

91.25
93.41
95.13
95.86
94.93
93.40
95.14
95.66
94.36

Case 12

D1_BM
D1_PB
D3_PB
D8_PB
D15_BM
D15_PB
D22_PB
D42_BM
D42_PB
D71_PB

97.44
97.62
97.52
97.37
97.11
97.12
97.51
97.71
95.86
96.89

91.02
94.00
91.33
94.75
94.80
95.11
97.11
93.75
94.11
93.99

% Reads Aligned
94.55
94.90
95.16
93.80
94.11
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%Selected Bases
96.65
94.88
95.92
94.92
95.46

Table 4-4.

(Continued)

Case #
Case 13

Sample
D1_PB
D3_PB
D8_PB
D15_BM
D15_PB
D22_PB
D42_PB

Case 14

D1_BM
D1_PB
D3_PB
D8_PB
D15_BM
D15_PB
D22_PB
D42_PB
D64_PB

% Reads Aligned
97.71
97.67
95.47
96.40
95.36
96.18
95.71
96.10
95.94
95.83
95.62
95.95
96.33
93.85
64.76
95.92
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%Selected Bases
97.96
91.92
97.81
96.95
96.54
98.42
97.77
96.80
96.01
98.00
96.96
96.15
97.85
97.71
97.62
97.49

Non-synonymous Mutation Detection in Whole-exome Captured Libraries
Mutation detection in whole exome captured samples was challenged by the
extremely high number of mutations detected per sample, the low MAF detected, the low
depth of coverage, and high error rate; hence, rendering the discrimination of false
positive from true positive calls difficult (Figure 4-3).
Non-synonymous Mutation Detection in Targeted Captured Libraries
Correlation between WBCs and Cf-DNA yield. A moderate significant
correlation existed between total leukocytic count (TLC) and Cf-DNA yield (spearman’s
coefficient: r=0.33; p-value=0.0029) (Figure 4-4).
However, when samples were grouped according to WBCs into low (TLC<1) and
high (TLC ≥1), no significant difference existed between the two groups. The mean CfDNA yield for the high group was 43.53 ng (Sd=99.48 ng); whereas for the low group
the mean Cf-DNA yield was 12.8 ng (Sd=13.69 ng) (p-value = 0.3352). The median CfDNA yield for the High group was 8.545 ng (IQR=17.79 ng); whereas for the low group,
the median Cf- DNA yield was 6 ng (IQR=6.9975ng) (p-value = 0.21).
Using multivariate analysis by Induction day; D22 yield was significantly
different from each of D1 (p=0.021), D3 (p=0.0091) and D8 (p=0.018) (Table 4-5).
Concordance between PB plasma Ct-DNA and WES in BM biopsy at
diagnosis. WES of bone marrow biopsy obtained at diagnosis reported 13 clinically
relevant somatic SNV in 8 patients (Table 4-6). The MAF of SNVs detected in WES BM
biopsy ranged from 6-74% (mean 37.2%; SD 17.13% and median of 30%; IQR 15%).
Ct-DNA analysis of diagnostic PB plasma detected 9 out the 13 mutations. The
MAF of SNVs ranged from 2.22-41.27% (mean 24.9%; SD 19.6% and median of 27.6%;
IQR 29.3%). PIK3CD was not included in our ALL custom gene panel nor were the
specific exons of CCND3 or TRRAP in which the mutations were detected. For Case10,
diagnostic PB plasma was not banked. Interestingly, analysis of Case10_D15 plasma
sample detected the mutation at an AF of 0.79%. Hence Ct-DNA analysis in PB plasma
showed 100% concordance with BM biopsy.
In Ct-DNA; somatic SNVs in the RAS/MAPK pathway represented ∼ 44% (3
NRAS and 1 KRAS mutation) of the detected mutations followed by JAK2 representing
∼ 33% of the detected mutations.
Regarding the correlation between MAF detected in PB plasma Ct-DNA and that
detected in BM biopsy samples (whole exome clinical sequencing) at diagnosis, a
moderate correlation was detected (Pearson coefficient r=0.53). (Figure 4-5 and Figure
4-6).
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Figure 4-3. Non-synonymous Mutations (Filtered Variant Calls) for Case#2
Whole Exome-captured Libraries
(Personal communication from Ousman Mahmoud Charles Gawad Lab. St. Jude
Children’s Research Hospital on March 6 th 2018).
t

Figure 4-4.

Correlation Between TLC (cells*10e9/L) and Cf-DNA Yield (ng)
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Table 4-5.
Median DNA Yield and TLC at Different Time Points During
Remission Induction Therapy
Induction Day
D1
D3
D8
D15
D22
EOI

Median TLC
(cells*10e9/L)
4.90
2.90
1.40
1.30
2.05
2.20

Median Cf-DNA Yield
(ng)
17.62
32.94
12.78
7.02
5.99
10.71

Table 4-6.
Clinically Relevant Single Nucleotide Somatic Variants MAF in BM
Biopsy WES and PBPL Ct-DNA at Diagnosis
Case#

Alteration

HGVS Nomenclature

Case 1
Case 2

NRAS Q61K
JAK2 R683G
JAK2 L884P
KRAS G13D
CCND3 E236K
NOTCH1 L1678P
PIK3CD E1021K
JAK2 R683S
KRAS A146V
NRAS G12S
SMARCA4 N817K
TRRAP E3107K
NRAS G12D

NM_002524:c.181C>A; p.Gln61Lys
NM_004972:c.2047A>G; p.Arg683Gly
NM_004972:c.2651T>C; p.Leu884Pro
NM_033360:c.38G>A; p.Gly13Asp
NM_001760:c.706G>A;p.Glu236Lys
NM_017617:c.5033T>C;p.Leu1678Pro
NM_005026:c.3061G>A;p.Glu1021Lys
NM_004972:c.2049A>T; p.Arg683Ser
NM_033360:c.437C>T; p.Ala146Val
NM_002524:c.34G>A; p.Gly12Ser
NM_001128849:c.2451C>A; p.Asn817Lys
NM_003496:c.9319G>A; p.Glu3107Lys
NM_002524:c.35G>A; p.Gly12Asp

Case 3
Case 4

Case 7
Case 10
Case 11

Case 13
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WES BM
Biopsy AF (%)

Ct-DNA
PBPL AF (%)

28
17
24
51
33
38
45
43
6
30
30
27
74

34.03
4.19
37.41
2.22
------27.64
-----41.27
-----10.7
8.09
-----58.5

Figure 4-5.
Diagnosis

MAF in Diagnostic BM Biopsy (WES) and PB Plasma Ct-DNA at

Figure 4-6. Correlation Between MAF in BM Biopsy (WES) and PB Plasma CtDNA at Diagnosis
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Concordance between PB plasma Ct-DNA and BM plasma Ct-DNA at
diagnosis. For the 9 cases in which clinically relevant mutations were detected, only 2
(Case#2 and #3) had BM plasma analyzed at diagnosis. The MAF of the 3 mutations
detected in Ct-DNA of PB plasma and BM plasma showed high concordance (Pearson’s
coefficient r=1; p-value=0.0099) (Figure 4-7 and Figure 4-8).
Monitoring clonal dynamics and disease response throughout remission
induction therapy. For those SNVs shared between diagnostic BM biopsy samples
(WES) and PB plasma, Ct-DNA analysis in sequential plasma samples successfully
captured the change in MAF across multiple induction time points. For all cases, the
mutations were still detected in D3 plasma sample at a comparable or higher level for
most cases. For all 7 cases, none of the SNVs re-emerged at a later time point after being
undetected (Table 4-7).
Comparison of Ct-DNA analysis and FC-MRD across multiple time points.
For cases in which mutations detected in clinical WES of BM biopsy, comparing MRD
detection as a categorical variable (i.e. FC-MRD positivity/negativity and
detection/absence of the initially specified mutation in Ct-DNA) at different induction
time points (Table 4-8 ) demonstrated the following:
D8 Induction. FC-MRD in PB demonstrated 50% concordance with PB plasma
Ct-DNA.
D15 Induction. FC-MRD in BM demonstrated 50% concordance with PB
plasma Ct-DNA.
D22 Induction. FC-MRD in BM showed 100% concordance PB Ct-DNA; CtDNA analysis successfully captured mutations in the two FC-MRD positive cases.
EOI. All samples were negative by both techniques.
Detailed description by case is provided below:
Case 1 Ct-DNA analysis of case 1 (B-cell hyperdiploid) demonstrated the
presence of NRAS Q61K mutation at diagnosis at an allele frequency of 32.8% in PB
plasma (BM plasma samples was not available for this case) in concordance with the
BM-NGS clinical report. Reports previously detected the existence of RAS mutation at
its highest prevalence in hyperdiploid ALL and were previously shown to confer
resistance to methotrexate, prednisone; and sensitivity to VCR.
The change in FC-MRD and MAF in Ct-DNA followed the same pattern. In
concordance with FC-MRD positivity on D15 and D22, NRASQ61K was detected (at a
decreased allele frequency). At EOI, the patient achieved a negative FC-MRD and the
NRAS Q61K was undetected at the assay threshold (Figure 4-9A and B).
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Figure 4-7.

MAF (%) in BM Plasma and PB Plasma in Ct-DNA at Diagnosis

Figure 4-8. Pearson’s Correlation Between MAF Detected in Ct-DNA PB Plasma
and BM Plasma
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Table 4-7.

MAF in Ct-DNA Across Multiple Induction Time Points
MAF (%)

Case#

Mutation

D1 Ind.

D3 Ind.

Case1
Case2

D8 Ind.

D15 Ind.

D22 Ind.

EOI

NRAS Q61K
JAK2 R683G

34.03
4.19

----2.48

----2.67

2.33
0

6.38
0

0
0

JAK2 L884P

37.41

37.80

0

0

-----

0

Case 3
Case4
Case 7

KRAS G13D
NOTCH1 L1678P
JAK2 R683S

2.22

3.16

43.38

0

0

0

27.64
41.27

11.41
38.01

3.33
15.29

4.76
0.98

0
1.13

0
0

Case 11

NRAS G12S

10.70

44.71

0

0

0

0

8.09

43.69

0

0

0

0

Case 13

SMARCA4 N817K
NRAS G12D

58.50

48.74

24.16

0

0

0

Only cases with mutations detected in clinical WES of BM biopsy are included.

Table 4-8.

Case#
Case 1
Case 2
Case 3
Case 4
Case 7
Case 11
Case 13

FC-MRD Detection at Multiple Induction Time Points

D8 PB
0.408
0.071
0.013
<0.01
0.738
0.018
<0.01

MRD (%)
D15 BM
D22 BM
6.82
2.12
0.01
NA
2.15
<0.01
<0.01
NA
1.502
0.421
0.014
NA
<0.01
NA

EOI BM
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01

Only cases with mutations detected in clinical WES of BM biopsy are included.
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(A)

(B)

Figure 4-9. Case#1 Change in Ct-DNA MAF and FC-MRD Throughout
Induction Therapy
(A)Change in NRAS Q61K MAF in PB plasma Ct-DNA throughout induction.
(B)FC-MRD in BM samples (left) and PB samples (right).
(Personal communication with Ousman Mahmoud on 28th March 2018, Charles Gawad
Lab. St. Jude Children’s Research Hospital).
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Case 2. Samples for all the study specified time points were analyzed. At
diagnosis, the two JAK2 mutations (JAK2 L884P and JAK2 R683G) were detected in
both BM plasma and PB blood plasma samples, at comparable allele frequency. On D8
Induction, JAK2 R683G was still detected, coinciding with a positive PB FC-MRD.
However, D15 Ct-DNA analysis revealed no mutations in either BM plasma or PB
plasma, whereas FC-MRD was still detected at a borderline value of 0.01%. At end of
induction, both assays were concordant showing a negative result (Figure 4-10A and B).
Case 3. At diagnosis, Ct-DNA analysis of this case (B-cell hyperdiploid) detected
KRASG13D in BM plasma and PB plasma at diagnosis. The MAF in BM biopsy sample
was 51% whereas Ct-DNA captured the same mutation at an allele frequency of 2.2%.
KRASG13D was not detected in D15 samples (BM plasma and PB plasma) whereas FCMRD was positive (2.15%).
Other mutations detected in the plasma samples at different time points require
further computational analysis work to confirm them as true variants. Taking into
consideration those mutations, Ct-DNA analysis showed concordance with FC-MRD,
being detectable on both D8 and D15.
Additionally, two of the captured mutations remained positive at D22 and EOI in
discordance with FC-MRD (Figure 4-11A and B).
Case 4. This patient comprises a T-cell ALL CNS-positive patient. At diagnosis,
PB Ct-DNA analysis revealed KRAS G12D and NOTCH1 L1678P mutations (diagnostic
BM plasma sample was not banked). Interestingly; Negative FC-MRD (<0.01%) was
detected in D8 PB, D15 BM and at end of induction; whereas, Ct-DNA analysis detected
NOTCH1 L1678P in D8 and D15 PB plasma and KRAS G12D in D15 BM plasma and
PB plasma. Later during the course therapy, this patient experienced CNS relapse and an
increase in BM FC-MRD (0.003%) (Figure 4-12A and B).
Case 7. Ct-DNA analysis detected a single JAK2 mutation (JAK2 R683S) in PB
plasma at diagnosis (diagnostic BM plasma sample was not banked). The MAF of the
aforementioned mutation was comparable to that detected in diagnostic BM biopsy by
clinical WES. The patient achieved a negative FC-MRD (<0.01%) as well as, an
undetectable JAK2R683S only by the end of induction hence, all other measured points
were considered positive by both techniques. However, FC-MRD decreased between D15
and D22 whereas the MAF in Ct-DNA showed a slight increase between the same time
points.
Ct-DNA detected KRAS G12D with changing allele frequency across different
time points for which further computational analysis is needed, to determine whether
KRAS G12D is a false positive call or not. KRAS G12D was still detected at EOI
(Figure 4-13A and B).
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(A)

(B)

Figure 4-10. Case#2 Change in Ct-DNA MAF and FC-MRD Throughout
Induction Therapy
(A) Change in JAK2 MAF in Ct-DNA throughout induction in BM samples (left) and PB
samples (right).
(B) Change in FC-MRD throughout induction therapy in BM samples (left) and PB
samples (right).
(Personal communication with Ousman Mahmoud on 28th March 2018, Charles Gawad
Lab. St. Jude Children’s Research Hospital).
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(A)

(B)

Figure 4-11. Case#3 Change in Ct-DNA MAF and FC-MRD Throughout
Induction Therapy
(A) Change in MAF in Ct-DNA throughout induction therapy in BM samples (left) and
PB samples (right).
(B) Change in FC-MRD throughout induction therapy in BM samples (left) and PB
samples (right).
(Personal communication with Ousman Mahmoud on 28th March 2018, Charles Gawad
Lab. St. Jude Children’s Research Hospital).
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(A)

(B)

Figure 4-12. Case#4 Change in Ct-DNA MAF and FC-MRD Throughout
Induction Therapy
(A) Change in MAF in Ct-DNA throughout induction therapy in BM samples (left) and
PB samples (right).
(B) Change in FC-MRD throughout induction therapy in BM samples (left) and PB
samples (right).
(Personal communication with Ousman Mahmoud on 28th March 2018, Charles Gawad
Lab. St. Jude Children’s Research Hospital).
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(A)

(B)

Figure 4-13. Case#7 Change in Ct-DNA MAF and FC-MRD Throughout
Induction Therapy
(A) Change in MAF in Ct-DNA throughout induction therapy in BM samples (left) and
PB samples (right).
(B) Change in FC-MRD throughout induction therapy in BM samples (left) and PB
samples (right).
(Personal communication with Ousman Mahmoud on 28th March 2018, Charles Gawad
Lab. St. Jude Children’s Research Hospital).
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Case 11. The clinical WES detected 3 mutations in the diagnostic BM sample
(NRAS G12S, SMARCA4 N817K and TRRAP E3107K). Ct-DNA analysis in PB
plasma detected NRAS G12S and SMARCA4 N817K (the exon in which the TRRAP
mutation was detected was not included in our ALL customized gene panel). In
discordance with FC MRD, both mutations were undetected on D8 and D15 induction by
Ct-DNA analysis (Figure 4-14A and B).
Case 13. NRASG12D was detected in the PB plasma at diagnosis. Despite that
peripheral blood FC-MRD on D8 was negative, NRASG12D mutation was detected in
Ct-DNA at a relatively high allele frequency of 24%. On D15, both techniques showed a
negative result (Figure 4-15A and B).
Single nucleotide variants captured in cases#5, 6, 8, 9, 12 and 14 require further
analysis to discriminate true variants from false positives. (Figure 4-16A and B through
4-21A and B).
The following analysis considers the whole number of mutations detected in the
studied in 13 patients (Table 4-2 and Figure 4-9A and B through Figure 4-21A and B).
This data is liable to change upon confirming that the detected variants as true calls.
D8 Induction. Ten patients who had detectable FC-MRD on D8. Ct-DNA
analysis was not done for one case at this time point, whereas Ct-DNA analysis in PB
plasma showed a positive result in 8 out of 9 patients (∼88.8%). Only 3 patients had
MRD <0.01% by FC; in one of the two patients FC-MRD was still detected at a level of
0.003%. Ct-DNA analysis showed to be positive in the 3 patients detecting a range of 1-3
mutations.
D15 Induction. FC-MRD was evaluated in BM for the 13 cases. FC-MRD level
was undetected (<0.01%) in 2 cases, ≥ 0.01%- < 1% in 6 cases and ≥ 1% in 5 cases.
In the first group of patients where FC-MRD <0.01%, Ct-DNA analysis and FCMRD results were discordant. Ct-DNA analysis of BM plasma as well as, PB plasma
showed a positive result for both cases.
In the group of patients whose FC-MRD was ≥ 0.01%- < 1%; 5 out of 6 patients
had samples available for Ct-DNA analysis. For the 5 patients; Ct-DNA analysis was
carried out in both BM plasma and PB plasma (10 samples). Ct-DNA showed a positive
result only in 2 cases (40%). Ct-DNA analysis results were concordant between PB
plasma and BM plasma in all 5 cases.
In patients with FC-MRD ≥ 1, Ct-DNA in PB plasma analysis was positive in all
of the 4/5 cases (80%) whereas Ct-DNA in BM plasma analysis was positive in the 5/5
cases (100%).
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(A)

(B)

Figure 4-14. Case#11 Change in Ct-DNA MAF and FC-MRD Throughout
Induction Therapy
(A) Change in MAF in Ct-DNA throughout induction therapy in PB samples.
(B) Change in FC-MRD throughout induction therapy in BM samples (left) and PB
samples (right).
(Personal communication with Ousman Mahmoud on 28th March 2018, Charles Gawad
Lab. St. Jude Children’s Research Hospital).
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(A)

(B)

Figure 4-15. Case#13 Change in Ct-DNA MAF and FC-MRD Throughout
Induction Therapy
(A) MAF in Ct-DNA in D15 BM sample (left), Change in MAF in Ct-DNA throughout
induction therapy in PB samples (right).
(B) Change in FC-MRD throughout induction therapy in BM samples (left) and PB
samples (right).
(Personal communication with Ousman Mahmoud on 28th March 2018, Charles Gawad
Lab. St. Jude Children’s Research Hospital).
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(A)

(B)

Figure 4-16. Case#5 Change in Ct-DNA MAF and FC-MRD Throughout
Induction Therapy
(A) Change in MAF in Ct-DNA throughout induction therapy in BM samples (left) and
PB samples (right).
(B) Change in FC-MRD throughout induction therapy in BM samples (left) and PB
samples (right).
(Personal communication with Ousman Mahmoud on 28th March 2018, Charles Gawad
Lab. St. Jude Children’s Research Hospital).
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(A)

(B)

Figure 4-17. Case#6 Change in Ct-DNA MAF and FC-MRD Throughout
Induction Therapy
(A) Change in MAF in Ct-DNA throughout induction therapy in BM samples (left) and
PB samples (right).
(B) Change in FC-MRD throughout induction therapy in BM samples (left) and PB
samples (right).
(Personal communication with Ousman Mahmoud on 28th March 2018, Charles Gawad
Lab. St. Jude Children’s Research Hospital).
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(A)

(B)

Figure 4-18. Case#8 Change in Ct-DNA MAF and FC-MRD Throughout
Induction Therapy
(A) Change in MAF in Ct-DNA throughout induction therapy in BM samples (left) and
PB samples (right).
(B) Change in FC-MRD throughout induction therapy in BM samples (left) and PB
samples (right).
(Personal communication with Ousman Mahmoud on 28th March 2018, Charles Gawad
Lab. St. Jude Children’s Research Hospital).
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(A)

(B)

Figure 4-19. Case#9 Change in Ct-DNA MAF and FC-MRD Throughout
Induction Therapy
(A) Change in MAF in Ct-DNA throughout induction therapy in BM samples (left) and
PB samples (right).
(B) Change in FC-MRD throughout induction therapy in BM samples (left) and PB
samples (right).
(Personal communication with Ousman Mahmoud on 28th March 2018, Charles Gawad
Lab. St. Jude Children’s Research Hospital).
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(A)

(B)

Figure 4-20. Case#12 Change in Ct-DNA MAF and FC-MRD Throughout
Induction Therapy
(A) Change in MAF in Ct-DNA throughout induction therapy in BM samples (left) and
PB samples (right).
(B) Change in FC-MRD throughout induction therapy in BM samples (left) and PB
samples (right).
(Personal communication with Ousman Mahmoud on 5th March 2018, Charles Gawad Lab.
St. Jude Children’s Research Hospital).
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(A)

(B)

Figure 4-21. Case#14 Change in Ct-DNA MAF and FC-MRD Throughout
Induction Therapy
(A) Change in MAF in Ct-DNA throughout induction therapy in BM samples (left) and
PB samples (right).
(B) Change in FC-MRD throughout induction therapy in BM samples (left) and PB
samples (right).
(Personal communication with Ousman Mahmoud on 12th March 2018, Charles Gawad
Lab. St. Jude Children’s Research Hospital).
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End of induction (EOI). At end of induction, 12/13 patients achieved FC-MRD
negativity (<0.01%). In 6/12 cases (50%). Ct-DNA analysis showed a positive result in
either BM plasma (2 cases) or in both BM plasma and PB plasma (4 cases).
Ct-DNA analysis of PB plasma for case 14 showed a positive result in concordance with
FC-MRD positivity (BM plasma was not analyzed).
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CHAPTER 5. DISCUSSION
Clonal evolution represents a dynamic process; in which the genetic landscape
continuously changes in response to changes in the evolutionary pressure (i.e. therapy
selective pressure). [22] Discovering the extent of intratumor heterogeneity has far been
limited by the focus on large chromosomal aberrations to decipher the tumor clonal
structure as well as, the reduced sensitivity of the experimental techniques which lacked
the ability to detect smaller subclones. The introduction of second generation sequencing
has allowed for the deciphering of subclonal somatic mutations leading to a number of
remarkable studies that demonstrated the ALL relapse follows a pattern of branched
clonal evolution; linear evolution is rarely involved. [54] However, in most cases, studies
addressing the clonal dynamics in ALL relapse compared matched diagnosis/relapse/±
remission BM samples. In the exceptional cases, where relapse mutations (in few
patients) were backtracked to earlier remission time points [11], it was demonstrated that
an increase in MAF of relapse-mutations preceded clinical relapse and that subclonal
mutations persisting post induction therapy comprise clonal mutations at relapse. [7, 11]
Despite the seminal findings of these studies; techniques currently implemented
for the measurement of minimal residual disease lack the ability to capture the genetic
heterogeneity; providing a quantitative rather than a qualitative description of the change
in MRD. The ability to unveil the mutational profile and clonal dynamics and
composition in serial MRD samples would complement the analysis; hence improving its
predictive value. Moreover, the detection of drug-resistance variants in MRD samples,
will have a direct clinical implication in tailoring therapy.[22] Ct-DNA analysis in
sequential plasma samples have proved utility in mutational profiling and monitoring
change in clonal dynamics in various solid and liquid malignancies.
This study represents the first proof-of-concept study to assess the utility of CtDNA in tracking tumor dynamics in pediatric ALL. Initially, WES sequencing was
employed using a hybrid capture technique utilizing a whole exome gene panel targeting
19,396 genes and covering 51Mb of end-to-end tile probe space. Several studies have
shown the utility of WES in tracking mutational change in Ct-DNA in plasma of patients
with different types of cancer. However, those studies evaluated patients with advanced
solid tumors [130]; in a seminal study using WES, Ct-DNA was quantified using ddPCR
and Tam-Seq. and only patients with high allele frequency were selected for WES. In
our study however, the mean total yield of Cf-DNA from the samples ranged from 6ng to
32 ng on D22 and D3 respectively. WES detected a large number of SNVs at a low MAF,
was associated with a high false positive error rate, rendering true SNVs calling
problematic.
Next, our group developed an ALL custom gene panel to analyze Ct-DNA in
sequential peripheral blood and matched BM plasma samples, obtained at specified time
points during induction therapy. The study evaluated 14 pediatric ALL patients of
different B-cell and T-cell subtypes. The ALL customized gene panel was designed by
the lab. computational biologist to target 806 genes covering ≅ 1668 exons and 319.4 kb.
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The specific ALL custom gene panel designed includes genes with at least 3
mutations in SiTH database (derived from app. 500 patients). Mutations selected are
somatic non-synonymous SNVs found in T-ALL and B-ALL diagnostic and relapse
samples.
Genes included showed to overlap with at least one of the following categories (1)
Oncogenic pathway (2) Tumor suppressor genes (3) Relapse-specific genes (4) Drug
metabolism (5) CRISPR/Cas9 screening (unpublished data) (6) Genes associated with
glucocorticoid resistance (7) xGen® Pan-Cancer Panel (which includes list of genes
derived from TCGA; known to be mutated across multiple cancer types).
Implementation of CAPP-Seq. in NSCLC was associated with artifacts in 50% of
the positions sequenced, below a detection limit of 0.02%. In their efforts to suppress the
error associated with CAPP-Seq., molecular barcoding was employed and successfully
reduced the error.[123] Hence, we additionally used index barcoding for all target
captured cases.
The cases enrolled in this pilot study comprise different ALL subtypes; 11 cases
are BCP and 3 cases are T-cell; one of which with ETP. According to NCI risk criteria,
36.4% (4 cases) of the BCP were high-risk whereas 63.6% (7 cases) were standard risk.
According to Total XVII risk groups, 3 patients were stratified as low-risk, 2 patients as
high-risk whereas 9 patients comprised the standard- (intermediate) risk group. In Total
study XVII, NGS is implemented as a diagnostic clinical standard-of-care for all patients
enrolled in the protocol. WGS, WES and transcriptome sequencing are carried by the
clinical pathology lab.; genetic alterations with relevance to diagnosis or management are
reported in the patient clinical record. Total XVII therapy implies Flowcytometry based
MRD for response assessment during induction therapy and throughout treatment. During
induction, MRD is evaluated in BM on D15, D22 (in patients with D15 MRD ≥ 1%) and
at end of induction (D42); whereas MRD evaluation in PB is carried out on D8.
Sequential analysis of Ct-DNA in plasma was employed at equivalent time points; BMplasma was evaluated on D1, D15 and at end of induction; whereas PB-plasma was
evaluated on D1, D3, D15, D22 and at end of induction.
Total XVII induction therapy utilizes a 4-drug regimen during early induction
(prednisone, daunorubicin, vincristine and peg-asparaginase) followed by cytarabine,
cyclophosphamide and 6-mercaptopurine. Rituximab, bortezomib and dasatinib are
administered to select patients (Appendix C. Total XVII Remission Induction
Treatment Schedule). Hence, the study of somatic mutations in Ct-DNA offers a venue
for monitoring the change in clonal composition and dynamics in response to the multiagent regimen applied.
The first question was whether Ct-DNA analysis would capture those mutations
detected in BM biopsy samples or not. NGS (WES and WGS) reported 13 clinically
relevant mutations in the diagnostic BM samples of 8 out of 14 patients. Somatic
mutation detection in peripheral plasma Ct-DNA showed 100% concordance with WES
of BM biopsy at diagnosis. The ability of Ct-DNA analysis to capture all the detected
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clinically relevant mutations utilizing ≅ 1 ml of plasma demonstrates the utility of CtDNA application in ALL.
Next, we evaluated the correlation between the MAF detected by both techniques.
Studying the allele frequency of the 9 mutations detected in both BM biopsy and plasma
samples yielded a moderate correlation (Pearson’s coefficient = 0.53). The discrepancy
can be attributed to a number of general factors namely, the low amount of Cf-DNA
extracted (Median ∼ 17 ng) together with the fact that Cf-DNA is derived from various
sources. Additional factors related to our study cohort that might have led to the modest
correlation between MAF detected in BM WES and PB plasma Ct-DNA , are the small
number of patients with detectable mutations and the presence of more than one mutation
per sample (i.e. case 11 WES shows 3 mutations, each at an AF of ∼ 30% whereas
plasma sample showed only 2 out of the 3 mutations at a much lower AF hence, one
sample contributed to 22% of the dataset). Importantly, this discrepancy might in fact
reflect a real difference in the MAF between different body compartments hence,
reflecting tumor heterogeneity.
Additionally, Ct-DNA MAF was evaluated throughout the aforementioned time
points and change in MAF was studied in relation to FC-MRD at matched time points.
Although the study has not revealed the expected correlation between MAF and the
quantitative level of FC MRD; Ct-DNA and FC-MRD were qualitatively concordant for
50% of samples on D8 and D15 and 100% concordant at D22 and EOI.
Regarding the 7 cases in which mutations were shared between BM biopsy and
PB Ct-DNA; 2 cases (Case 1 and Case 7) showed concordance between FC-MRD and
Ct-DNA across all time points.
Two cases (Case 2 and Case 11) had no mutations detected in Ct-DNA at FCMRD positive time points. Case 11 harbored NRAS G12S, SMARCA4 N817K and
TRRAP E3107K as detected by clinical WES of the diagnostic BM biopsy. TRAPP exon
in which the mutation was detected was not included in our ALL custom gene panel.
Hence, the inability of Ct-DNA to track TRAPP mutation detected in the BM biopsy
sample might offer an explanation i.e. the positive FC-MRD might be attributed to the
clone harboring the TRAPP mutation. Further analysis for the samples including that
TRAPP exon might pose an answer. Also, the improvement of the analysis pipeline for
capturing true positive calls might reveal other mutations that were present in Case 2 yet
filtered out with the currently applied analysis pipeline.
For case 3, although the KRAS G13D was undetected on D15 in discordance with
a positive MRD (2.15%), KRAS G12D mutation was detected at an allele frequency of
15.9%. Importantly, KRAS G12D was not detected in the PB plasma nor the BM plasma
diagnostic samples; yet it was initially detected in D8 PB plasma. KRAS G12D
detected in PB plasma as well as BM plasma on D15 and persisted till end of induction
(at a lower allele frequency). ITSN1 L1393M was also detected at different allele
frequencies across multiple time points and persisted till end of induction. Although
further confirmation of these mutations as true positive is required, they might provide an
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explanation for D15 discordance between FC-MRD and Ct-DNA on D15. Additionally,
the fact that such mutations were still detected at EOI whereas the FC-MRD was
negative. The aforementioned findings show the ability of the technique to unveil the
clonal composition in FC-MRD positive patients as well as, its sensitivity to capture
mutations at lower MAF in FC-MRD negative patients.
Case 4 showed a negative FC-MRD on D15 however NOTCH1 L1678P (detected
at diagnosis) was still detected by Ct-DNA analysis in both PB plasma and BM plasma.
Hence, it provides a confirmation for the sensitivity of the technique to unravel the clonal
composition and detect mutations at low mutation allele frequency in FC-MRD negative
patients. The same is true for Case 13 where NRASG12D mutation was detected in CtDNA at a relatively high allele frequency of 24% on D8 whereas the FC-MRD was
negative.
The different scenarios mentioned above demonstrate a potential role for
sequential analysis Ct-DNA as a complementary technique to FC MRD; providing an
insight into the clonal composition of the MRD and consequently guiding treatment
decisions. The non-invasiveness of the technique as well as the relative low cost further
supports the utility of incorporation in the clinical management.
Ct-DNA has a potential therapeutic implication in guiding therapy. Despite the
small number of patients studied, Ct-DNA successfully captured clinically relevant
mutations at diagnosis as well as throughout induction therapy. As such; several future
therapeutic options might be incorporated into clinical practice. Case 2 provides a good
example; as noted in the clinical sequencing report, the assay (WES) lacks capability to
detect whether the 2 JAK mutations exist in cis or trans yet; it is important to consider
that the presence of L884P mutation confers resistance to type 2 JAK2 inhibitors in
CRLF2/JAK2 R683G cells (case_2 is CRLF2 positive). In such case, combination of type
I/II JAK2 inhibitors might offer a treatment option to overcome resistance.[131]
Monitoring the relevant change in MAF of both mutations throughout therapy might
provide a deeper insight into the possible therapeutic options.
Further work would be needed to study a larger number of patients and advance
the technique and the analysis pipelines in order to correctly detect real mutations and
decrease false positive calls.
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APPENDIX A.LIST OF GENES INCLUDED IN ALL GENE PANEL

ABP1
ACE2
ACOX1
ACP5
ACSM2B
ACSM4
ACTL6B
ACTN2
ADD1
ADH6
ADNP
ADRBK1
AFAP1
AFF2
AFF3
AGXT2L1
AHNAK
AHNAK2
AHRR
AKR1B1
AKR1C2
AKT1
ALG13

ALPK2
ANAPC1
ANK3
ANKRD12
ANKRD30B
ANKRD43
AOX1
APC
APOB48R
AR
ARAP1
ARHGAP20
ARID1A
ARID1B
ARID2
ARID5B
ASH1L
ASXL1
ASXL2
ASXL3
ATF7IP
ATG4A
ATM

ATP13A4
ATP5A1
ATP8A1
ATP8A2
ATRNL1
ATRX
AXIN2
AXL
AZI1
BAI2
BAI3
BAZ2A
BBS9
BCOR
BCORL1
BCR
BIRC6
BMP1
BRAF
BRCA1
BRPF1
BRSK1
BVES

Gene Name
C11orf41
C11orf82
C12orf51
C12orf64
C12orf66
C13orf40
C14orf4
C16orf52
C1QTNF3
C6orf97
CABLES1
CAD
CAMSAP1L1
CAND1
CASP4
CBS
CBX4
CCBE1
CCDC114
CCDC147
CCND3
CD101
CD36
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CD6
CDC20B
CDC6
CDH18
CDH23
CDH8
CDH9
CDK16
CDKN2A
CDKN2AIP
CDR2L
CDYL2
CELSR2
CENPC1
CENPE
CEP290
CES1
CFTR
CHD1
CHD2
CHD4
CHD7
CHD9

CHRM2
CHRNA4
CLCA4
CLCN3
CLEC4M
CLIC3
CMYA5
CNOT1
CNTN1
CNTN3
CNTN5
CNTN6
CNTNAP2
CNTNAP5
COPS2
CPB1
CREBBP
CREBBP,CREBBP
CRLF2
CSMD1
CSMD2
CSMD3
CSPG4

CTCF
CTNND1
CTNND2
CTR9
CUBN
CXorf22
CXorf23
CXorf57
CXorf59
CYP2C8
CYP4F22
DAAM2
DACH1
DACT2
DCAF10
DCHS2
DCST2
DDX3X
DEPDC5
DHX33
DIAPH2
DIAPH3
DISC1

DLC1
DMBT1
DNAH2
DNAH5
DNAH8
DNAH9
DNM2
DNMT3A
DNMT3B
DOCK11
DOCK5
DOCK6
DPH1
DPP3
DPT
DPYS
DRD1
DRP2
DSC1
DSCAM
DSG2
DSG4
DSP

DST
DTX3L
DYNC2H1
DYSF
ECT2L
EED
EEF1A2
EGFLAM
EGFR
EGR3
EHMT2
EIF4A1
ELAVL2
ELF1
ENPP5
ENPP6
EP300
EPPK1
ERC2
ERCC6
ERG
ESX1
ETV1

Gene Name
ETV6
ETV6,ETV6,ETV6
EVC2
EZH2
F13B
FAAH
FAT1
FAT4
FBN1
FBN2
FBN3
FBXL19
FBXO18
FBXW7
FBXW7,FBXW7
FCGBP
FCRL2
FCRLA
FER1L6
FEZF1
FGF12
FGF13
FGF9
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FGFR2
FGFR3
FHOD1
FLNC
FLRT2
FLT3
FLT3,FLT3
FMN2
FMN2,FMN2
FMOD
FMR1
FN1
FNDC1
FOXA1
FOXO4
FOXP2
FRAS1
FREM2
FRMD4A
FRMPD2
FSIP2
FURIN
GAD1

GALNTL4
GAS2L3
GATA2
GATA3
GBP7
GCKR
GGT1
GIGYF2
GIGYF2,GIGYF2
GIPR
GLIS2
GLTSCR1
GNAQ
GNB1
GPC6
GPR116
GPR142
GPR98
GREB1
GRIA1
GRIA2
GRID1
GRID2

GRIN2A
GRM5
GRPR
GSTA4
GYS1
H3F3A
HADHA
HAT1
HCN4
HCRTR1
HDAC2
HDAC5
HDAC7
HDAC9
HGF
HIST1H1B
HIST1H1C
HIVEP3
HK2
HLF
HMCN1
HNF4G
HNRNPA1

HRNR
HUWE1
HYDIN
IDH1
IFIH1
IGSF9B
IKZF1
IKZF3
IL15RA
IL1RAPL1
IL7R
IL7R,IL7R
IL7R,IL7R,IL7R
INPP4B
IQCB1
ITGA6
ITGAD
ITGB4
ITGB8
ITIH2
ITPKC
ITPR1
ITSN1

Gene Name
JAG1
KIAA0922
JAK1
KIAA1024
JAK2
KIAA1109
JAK3
KIAA1217
JAKMIP1
KIAA1244
JARID2
KIAA1409
JMY
KIAA1715
KAL1
KIF15
KCNA4
KIF21A
KCNG2
KIF4A
KCNH1
KLF4
KCNH2
KLK9
KDM1A
KNDC1
KDM2B
KPNB1
KDM5B
KRAS
KDM5C
KRAS,KRAS
KDM6A
KRT33A
KDM6A,KDM6A
L3MBTL1
KDM6A,KDM6A,KDM6A L3MBTL4
KIAA0240
LAMA2
KIAA0368
LAMB1
KIAA0430
LAMC1
KIAA0802
LEPREL2

83

LGALS12,LGALS12
LGALS4
LIFR
LIMD1
LOXL3
LPHN1
LPHN2
LPO
LRFN2
LRP1B
LRP2
LRRK2
LSG1
LTBP1
LTBP2
LUC7L2
LYPD2
LZTR1
MADD
MAGEB2
MAGED2
MAGI3
MAGI1

MAMDC2
MAP1B
MAP2
MAP2K4
MAP3K4
MAP4K5
MAPK9,MAPK9
MARCKS
MATN4
MBD1
MCF2
MCM2
MCTP1
MDGA2
MECP2
MED12
MED13
MGA
MGAT1
MGAT4C
MGAT5B
MID1
MLL,MLL

MLL2
MLL2,MLL2
MLL3
MLL4
MME
MMS19
MPO
MRC2
MSH6
MSN
MTA1
MTHFD1
MTNR1A
MTOR
MTUS2
MVP
MXRA5
MYB
MYC
MYCBP2
MYST3,MYST3
NALCN
NAT1

NAV3
NBEA
NCCRP1
NCKAP1
NCKAP5
NCOR1
NCOR2
NDUFS6
NEDD4L
NEGR1
NEIL3
NEK10
NELL1
NEXN
NF1
NF1,NF1
NHSL1
NIPBL
NKX2-8
NLGN4X
NLRC4
NLRP3
NLRP8

Gene Name
NNMT
NUDT10
NOD1
NXF1
NOS1
NYNRIN
NOS1AP
OGT
NOS2
OGT,OGT
NOS3
OLFM3
NOTCH1
OPHN1
NOTCH2
OPRM1
NOTCH3
OR5I1
NOTUM
OTUD7A
NOVA1
PAK2
NOX1
PAMR1
NR3C1
PAPPA2
NRAP
PARK2
NRAS
PAX5
NRAS,NRAS
PAX9
NRAS,NRAS,NRAS PBRM1
NRK
PCDH1
NRXN1
PCDH15
NSD1
PCDHA3
NT5C1B
PCDHAC1
NT5C2
PCDHGA5
NT5C2,NT5C2
PCLO
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PCNX
PCSK2
PDCD2L
PDE11A
PDE3A
PDE7B
PDS5B
PDZD2
PDZRN4
PEG3
PER1
PHACTR2
PHF12
PHF6
PHF6,PHF6
PHF8
PHLDB1
PIK3CA
PIK3R1
PIK3R3,PIK3R3
PIWIL4
PKDREJ
PKHD1

PKHD1L1
PKN3
PKP2
PLCB2
PLCB3
PLCE1
PLS3
PLXNA2
PNMA2
POLB
POLD1
POLQ
POM121L12
PON3
POT1
PPFIA2
PPFIBP1
PPFIBP2
PPP1R10
PPP2R1A
PPP2R2C
PPYR1
PRAM1

PRDM1
PRDM15
PRDM2
PRDM9
PRKCD
PRKCE
PRKCQ
PRKCZ
PRKD1
PRKD2
PRKDC
PRMT3
PRPS1
PRRX1
PRSS22
PRSS3
PRUNE2
PRX
PSD4
PSMA7
PTCH1
PTGIS
PTPN11

PTPN11
PTPN13
PTPN14
PTPN3
PTPRF
PTPRG
PTPRN
PTPRT
PTPRZ1
PXDNL
RAB32
RAD21
RAI1
RB1
RBMX
RELN
RIMBP2
RIPK4
ROBO1
ROBO2
ROR1
RPL22
RPL5

RUNX1
RXFP2
RYR2
SAE1
SALL3
SCN5A
SERPINA1
SERPINA4
SERPINB10
SETD2
SETDB1
SH2B3
SH3KBP1
SHISA2
SHROOM2
SI
SIN3A
SLFN5
SLIT3
SLITRK2
SLITRK4
SMARCA4
SMARCB1

Gene Name
SMARCC1
SMC1A
SMC3
SNRNP200
SOX4
SOX6
SOX9
SPAST
SPEN
SPOP
SPTA1
SPTBN1
SPTBN5
SPZ1
SRRM2
SSPO
ST14
STAG2
STARD9
STK11
ACTC1
ADAMTS3
ADAP2
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AMOTL2
ARNT
ATG7
BAK1
BRD4
C12orf10
C14orf178
C2orf82
CAPN3
CASP5
CBX8
CCNDBP1
CD5L
CD79A
CPNE1
CPSF6
DDT
DNHD1
ECE2
EIF4EBP3
ENPEP
ERBB2
EXTL3

FAM96B
FARSB
FOLR1
FTH1
G6PC2
GHRL
GLIS1
GPR149
GPR6
HEY2
HIST1H3A
HIST1H3C
HSD3B1
IRGM
JPH3
KLF12
KLHDC4
LIMS2
LPA
LRIG2
LRRC34
LRRC58
LYPD4

MAP10
MYCN
NEUROG3
NRIP1
P2RY12
PCDHB16
PDCD6
PLCH2
PMAIP1
RPL22L1
RRP9
SERPINB7
SHC2
SHF
SPATA31E1
SUN2
SUPT6H
SUZ12
SVIL
SYNE1
SYNE2
SYT12
TAB2

TACC2
TACC3
TAF1
TAF15
TAF3
TATDN1,TATDN1
TBC1D9
TBL1XR1
TBX15
TBX18
TBX3
TCF3
TECTA
TET2
TET3
TGM4
THBS2
THSD7A
TIGD7
TLN2
TMC6
TMEM127
TMEM184A

Gene Name
TMEM205
TUBGCP6
TMTC1
TXNRD1
TMTC2
U2AF1
TNC
UBA2
TNFRSF13B
UBR2
TNIK
UBR4
TNN
UGT2A3
TP53
UHRF1
TP53,TP53
UHRF1BP1
TP53,TP53,TP53
UNC80
TPCN1
USH2A
TRIM39
USP5
TRMT1L
USP7
TRPM1
USP9X
TRPM3
UTY
TRPV2
VANGL1
TRRAP
VEZF1
TSC1
VPS13A
TSHZ2
VSIG2
TSKS
VWA3A
TTC17
VWA5A
TTC28
WBSCR17
TTC9
WDR16

WDR17
WHSC1
WNK3
WRN
WSCD2
WT1
WWC1
XBP1
XIRP2
XRRA1
ZAN
ZBTB3
ZEB2
ZFHX4
ZFP36L2
ZKSCAN4
ZMYM2
ZNF292
ZNF445
ZNF483
ZNF521
ZNF687
ZNRF2

ZSCAN20

(Personal communication with Ousman Mahmoud on 13th February 2018, Charles Gawad Lab. St. Jude Children’s Research Hospital)
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APPENDIX B.TOTAL XVII RISK STRATIFICATION
Criteria for Low-Risk (LR) ALL
• B-ALL with DNA index ≥1.16, t(12;21) Or age 1 to 9.9 years and presenting
WBC count <50 x 109/L plus
• Absence CNS 3 status, testicular leukemia, adverse genetic characteristics (t
(9;22); t(1;19); MLL gene re-arrangement, hypodiploidy and poor early response
defined as MRD ≥1% on D15 or ≥0.01% at end of remission induction.
Criteria for Standard-Risk (SR) ALL
• Patients with T- or B-ALL who do not meet the criteria for low-risk or high-risk
ALL.
Criteria for High-Risk (HR) ALL
• End of early intensification: MRD ≥0.1% + inadequate decrease in MRD levels
after 1-2 courses of Consolidation treatment
• End of remission induction: MRD ≥0.01% in hypodiploid patients.
• After re-induction II (Continuation W17): Persistent ≥ 0.01% MRD
• Increasing in MRD at ≥0.01% after remission induction
• Previously MRD-negative patients: Re-emergence of MRD at ≥0.01%
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APPENDIX C.TOTAL XVII REMISSION INDUCTION TREATMENT
SCHEDULE
Precursor B-cell ALL Remission Induction Treatment Schedule
Agent
Prednisone or Prednisolone
Vincristine
DAUNOrubicin
Pegaspargase
Cyclophosphamide
Cytarabine
Mercaptopurine

Schedule
Days 1-28
Days 1#, 8, 15, 22
Days 2# +/- 8
Days 4 and 23
Day 22
Days 22-25 & 29-32
Days 22-35

Bortezomib (No targetable lesions and Day 15 MRD ≥5%) on D29 and D32
Dasatinib (Ph+, Ph-like ABL1-class fusion only) starting on D15 except for select
cases
Rituximab is given on D3 (un-blinded randomization)
T-cell ALL Remission Induction Treatment Schedule
Agent
Prednisone or Prednisolone
VinCRIStine
DAUNOrubicin
Pegaspargase
Cyclophosphamide†
Cytarabine†
Mercaptopurine†

Schedule
Days 1-28
Days 1#, 8, 15, 22
Days 2#, 8, 15
Days 4 and 23†
Day 22
Days 22-25 and 29-32
Days 22-35

Bortezomib (No targetable lesions and Day 15 MRD ≥5%) on D29 and D32
Dasatinib (ABL1-class fusion only) starting on D15 except for select cases
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